{ "version": "2.2", "instance": { "fbio-20251231x10k.htm": { "nsprefix": "fbio", "nsuri": "http://www.fortressbiotech.com/20251231", "dts": { "schema": { "local": [ "fbio-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "fbio-20251231_cal.xml" ] }, "definitionLink": { "local": [ "fbio-20251231_def.xml" ] }, "labelLink": { "local": [ "fbio-20251231_lab.xml" ] }, "presentationLink": { "local": [ "fbio-20251231_pre.xml" ] }, "inline": { "local": [ "fbio-20251231x10k.htm" ] } }, "keyStandard": 440, "keyCustom": 266, "axisStandard": 41, "axisCustom": 1, "memberStandard": 43, "memberCustom": 141, "hidden": { "total": 23, "http://www.fortressbiotech.com/20251231": 3, "http://xbrl.sec.gov/dei/2025": 4, "http://fasb.org/us-gaap/2025": 16 }, "contextCount": 574, "entityCount": 1, "segmentCount": 199, "elementCount": 1176, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 1270, "http://xbrl.sec.gov/dei/2025": 43, "http://xbrl.sec.gov/cyd/2025": 15, "http://xbrl.sec.gov/ecd/2025": 5 }, "report": { "R1": { "role": "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R3": { "role": "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_ATZa30MH5EafYTxEqDv5fg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "fbio:PreferredStockSharesDesignated", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "fbio:PreferredStockSharesDesignated", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R4": { "role": "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_kLyGBn_6oUaYv8BvCmZWAw", "name": "fbio:GainLossOnRecovery", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R5": { "role": "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "995200300 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pteLtEL4M0ack96PTVq-WQ", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_pteLtEL4M0ack96PTVq-WQ", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R7": { "role": "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "longName": "995210101 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreements", "longName": "995210301 - Disclosure - Asset Purchase and Merger Agreements", "shortName": "Asset Purchase and Merger Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.fortressbiotech.com/role/DisclosureInventory", "longName": "995210401 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment", "longName": "995210501 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements", "longName": "995210601 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.fortressbiotech.com/role/DisclosureLicenseAgreements", "longName": "995210701 - Disclosure - License Agreements", "shortName": "License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssets", "longName": "995210801 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterest", "longName": "995210901 - Disclosure - Debt and Interest", "shortName": "Debt and Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpenses", "longName": "995211001 - Disclosure - Accounts Payable and Accrued Expenses", "shortName": "Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.fortressbiotech.com/role/DisclosureNonControllingInterests", "longName": "995211101 - Disclosure - Non-Controlling Interests", "shortName": "Non-Controlling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare", "longName": "995211201 - Disclosure - Net Loss per Common Share", "shortName": "Net Loss per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquity", "longName": "995211301 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211401 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.fortressbiotech.com/role/DisclosureEmployeeBenefitPlan", "longName": "995211501 - Disclosure - Employee Benefit Plan", "shortName": "Employee Benefit Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions", "longName": "995211601 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxes", "longName": "995211701 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformation", "longName": "995211801 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers", "longName": "995211901 - Disclosure - Revenues from Contracts and Significant Customers", "shortName": "Revenues from Contracts and Significant Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.fortressbiotech.com/role/DisclosureSubsequentEvents", "longName": "995212001 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_10_1_2025_To_12_31_2025_fm1RkdP11kOdy6Y7ciPqTQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2025_To_12_31_2025_fm1RkdP11kOdy6Y7ciPqTQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.fortressbiotech.com/role/DisclosureInventoryTables", "longName": "99930403 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables", "longName": "99930503 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930603 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_1x7Kd0aa7k2tWKYSjDrpvw", "name": "fbio:ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_1x7Kd0aa7k2tWKYSjDrpvw", "name": "fbio:ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables", "longName": "99930803 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables", "longName": "99930903 - Disclosure - Debt and Interest (Tables)", "shortName": "Debt and Interest (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "longName": "99931003 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTables", "longName": "99931203 - Disclosure - Net Loss per Common Share (Tables)", "shortName": "Net Loss per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables", "longName": "99931303 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99931403 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "99931603 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesTables", "longName": "99931703 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables", "longName": "99931803 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables", "longName": "99931903 - Disclosure - Revenues from Contracts and Significant Customers (Tables)", "shortName": "Revenues from Contracts and Significant Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails", "longName": "99940101 - Disclosure - Organization and Description of Business (Narrative) (Details)", "shortName": "Organization and Description of Business (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:NumberOfPartnerCompaniesThatArePubliclyTraded", "unitRef": "Unit_Standard_company_EiNdrD-rWUyH8c39agEppg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:NumberOfPartnerCompaniesThatArePubliclyTraded", "unitRef": "Unit_Standard_company_EiNdrD-rWUyH8c39agEppg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Dw_7gsaPSkeGkMbbcSsv3w", "name": "fbio:AssetsHeldForSale", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "fbio:AssetsHeldForSalePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_Dw_7gsaPSkeGkMbbcSsv3w", "name": "fbio:AssetsHeldForSale", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "fbio:AssetsHeldForSalePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)", "shortName": "Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R49": { "role": "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "longName": "99940301 - Disclosure - Asset Purchase and Merger Agreements - Checkpoint CVR Agreement (Details)", "shortName": "Asset Purchase and Merger Agreements - Checkpoint CVR Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IncreaseDecreaseInOtherOperatingLiabilities", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2025_To_7_31_2025_us-gaap_BusinessAcquisitionAxis_fbio_CheckpointMember__GXP6mbeF0muvA207chCJw", "name": "us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R50": { "role": "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "longName": "99940302 - Disclosure - Asset Purchase and Merger Agreements - Royalty Agreement (Details)", "shortName": "Asset Purchase and Merger Agreements - Royalty Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_V-bPZgs-z0iDoN6TGT1ohg", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R51": { "role": "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "longName": "99940303 - Disclosure - Asset Purchase and Merger Agreements (Narrative) (Details)", "shortName": "Asset Purchase and Merger Agreements (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DeconsolidationGainOrLossAmount", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_13_2025_To_5_13_2025_kEIKqXzDu0GKaZKhAnyNzQ", "name": "fbio:NumberOfDaysToDisposeOfAssetsPurchased", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R52": { "role": "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails", "longName": "99940401 - Disclosure - Inventory (Schedule of Inventory) (Details)", "shortName": "Inventory (Schedule of Inventory) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "longName": "99940501 - Disclosure - Property and Equipment (Schedule of Property, Plant and Equipment) (Details)", "shortName": "Property and Equipment (Schedule of Property, Plant and Equipment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "longName": "99940502 - Disclosure - Property and Equipment (Narrative) (Details)", "shortName": "Property and Equipment (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_2_1_2025_To_2_28_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_gbDvR-PJ4EeLDTSyYPwQQw", "name": "fbio:PropertyPlantAndEquipmentWriteOff", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R55": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "longName": "99940601 - Disclosure - Fair Value Measurements (Common Stock Warrant Liabilities) (Details)", "shortName": "Fair Value Measurements (Common Stock Warrant Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Dw_7gsaPSkeGkMbbcSsv3w", "name": "fbio:WarrantLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_fbio_CommonStockWarrantsMember_kTEW6PrABUSHdvBKhBLo7g", "name": "fbio:WarrantLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R56": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "longName": "99940602 - Disclosure - Fair Value Measurements (Narrative) (Details)", "shortName": "Fair Value Measurements (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "fbio:WarrantLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbio_AevitasMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Wowy2HDFVUaun3FTF23T0g", "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R57": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "longName": "99940603 - Disclosure - Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details)", "shortName": "Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_krPTOBh_oki93SepeZkTWw", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_ATZa30MH5EafYTxEqDv5fg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2022_srt_ConsolidatedEntitiesAxis_fbio_CheckpointMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5Bb1bhRrC0-o_NBNLe8GMw", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_ATZa30MH5EafYTxEqDv5fg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R58": { "role": "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "longName": "99940701 - Disclosure - License Agreements (R&D and Journey) (Details)", "shortName": "License Agreements (R&D and Journey) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "longName": "99940702 - Disclosure - License Agreements (Avenue) (Details)", "shortName": "License Agreements (Avenue) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_2_28_2023_To_2_28_2023_srt_ConsolidatedEntitiesAxis_fbio_AvenueTherapeuticsIncMember_us-gaap_TypeOfArrangementAxis_fbio_JM17LicenseAgreementForIntellectualPropertyRightsMember_RMklcxG4Y0CVmcQcOellJg", "name": "fbio:PaymentOfUpfrontFees", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_2_28_2023_To_2_28_2023_srt_ConsolidatedEntitiesAxis_fbio_AvenueTherapeuticsIncMember_us-gaap_TypeOfArrangementAxis_fbio_JM17LicenseAgreementForIntellectualPropertyRightsMember_RMklcxG4Y0CVmcQcOellJg", "name": "fbio:PaymentOfUpfrontFees", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails", "longName": "99940703 - Disclosure - License Agreements (Urica and Partner Companies) (Details)", "shortName": "License Agreements (Urica and Partner Companies) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_fbio_LicenseAgreementsMember_yJ_won_HaEGxO6zIsxKzJw", "name": "fbio:LicenseAgreementsUpfrontAndMilestonePayments", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_fbio_LicenseAgreementsMember_yJ_won_HaEGxO6zIsxKzJw", "name": "fbio:LicenseAgreementsUpfrontAndMilestonePayments", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "longName": "99940801 - Disclosure - Intangible Assets (Narrative) (Details)", "shortName": "Intangible Assets (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "longName": "99940802 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)", "shortName": "Intangible Assets (Schedule of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_fJxlD8iDREOVtDJMzEyy2w", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R63": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "longName": "99940803 - Disclosure - Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details)", "shortName": "Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_fJxlD8iDREOVtDJMzEyy2w", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R64": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "longName": "99940901 - Disclosure - Debt and Interest (Schedule of Debt) (Details)", "shortName": "Debt and Interest (Schedule of Debt) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R65": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "longName": "99940902 - Disclosure - Debt and Interest (Narrative) - 2024 Oaktree Note (Details)", "shortName": "Debt and Interest (Narrative) - 2024 Oaktree Note (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_7_25_2024_us-gaap_DebtInstrumentAxis_fbio_OaktreeNoteMember_aJxC2on6YEyqC1HUoXdrng", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R66": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "longName": "99940903 - Disclosure - Debt and Interest (Narrative) - 2020 Oaktree Note (Details)", "shortName": "Debt and Interest (Narrative) - 2020 Oaktree Note (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:LongTermNotesPayable", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_7_25_2024_us-gaap_DebtInstrumentAxis_fbio_OaktreeNote2Member_IrBOCdjmFUyCbZWoyRZOkQ", "name": "us-gaap:LongTermNotesPayable", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R67": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "longName": "99940904 - Disclosure - Debt and Interest (Narrative) - SWK Term Loan (Details)", "shortName": "Debt and Interest (Narrative) - SWK Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_27_2023_us-gaap_DebtInstrumentAxis_fbio_SwkTermLoanMember_X02v3E8SikGN5ZANzNfJcQ", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R68": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "longName": "99940905 - Disclosure - Debt and Interest (Narrative) - Urica Offering (Details)", "shortName": "Debt and Interest (Narrative) - Urica Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_ConsolidatedEntitiesAxis_fbio_Ur1TherapeuticsIncMember_RELDcRM_CEqjHyVJNZTVYQ", "name": "us-gaap:InterestExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_ConsolidatedEntitiesAxis_fbio_Ur1TherapeuticsIncMember_RELDcRM_CEqjHyVJNZTVYQ", "name": "us-gaap:InterestExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "longName": "99940906 - Disclosure - Debt and Interest (Ximino Settlement) (Details)", "shortName": "Debt and Interest (Ximino Settlement) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_8_31_2024_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_us-gaap_TypeOfArrangementAxis_fbio_XiminoSettlementMember_nnAv9zGLSkmCwDuL2mEoIQ", "name": "fbio:PartnerCompanyInstallmentPaymentsLicenses", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_8_31_2024_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_us-gaap_TypeOfArrangementAxis_fbio_XiminoSettlementMember_nnAv9zGLSkmCwDuL2mEoIQ", "name": "fbio:PartnerCompanyInstallmentPaymentsLicenses", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "longName": "99940907 - Disclosure - Debt and Interest (Interest Expense) (Details)", "shortName": "Debt and Interest (Interest Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:InterestExpenseDebt", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R71": { "role": "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "longName": "99941001 - Disclosure - Accounts Payable and Accrued Expenses (Details)", "shortName": "Accounts Payable and Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsScheduleOfNonControllingInterestsInConsolidatedEntitiesDetails", "longName": "99941101 - Disclosure - Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)", "shortName": "Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "As_Of_12_31_2025_srt_OwnershipAxis_fbio_JourneyMember_gYYt1Iffr0iuJieZZ1By5w", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_OwnershipAxis_fbio_JourneyMember_gYYt1Iffr0iuJieZZ1By5w", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails", "longName": "99941201 - Disclosure - Net Loss per Common Share (Schedule of potentially dilutive securities would be excluded from the computation of net loss per common share) (Details)", "shortName": "Net Loss per Common Share (Schedule of potentially dilutive securities would be excluded from the computation of net loss per common share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCommonStockDetails", "longName": "99941301 - Disclosure - Stockholders' Equity (Common Stock) (Details)", "shortName": "Stockholders' Equity (Common Stock) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "longName": "99941302 - Disclosure - Stockholders' Equity (Series A Cumulative Redeemable Perpetual Preferred Stock Dividends) (Details)", "shortName": "Stockholders' Equity (Series A Cumulative Redeemable Perpetual Preferred Stock Dividends) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:PreferredStockAmountOfPreferredDividendsInArrears", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R76": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails", "longName": "99941303 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense Narrative) (Details)", "shortName": "Stockholders' Equity (Stock-Based Compensation Expense Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R77": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails", "longName": "99941304 - Disclosure - Stockholders' Equity (Stock Based Compensation Plans of Partner Companies) (Details)", "shortName": "Stockholders' Equity (Stock Based Compensation Plans of Partner Companies) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_ConsolidatedEntitiesAxis_fbio_CypriumMember_us-gaap_PlanNameAxis_fbio_TwoThousandSeventeenLongTermIncentivePlanMember_aAIUN7a010aX0-FTpY2_LA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R78": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "longName": "99941305 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense) (Details)", "shortName": "Stockholders' Equity (Stock-Based Compensation Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AwardTypeAxis_fbio_EmployeeAndNonemployeeAwardsMember_3jg47rkdC02uq7TVo_ekpA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R79": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "longName": "99941306 - Disclosure - Stockholders' Equity (Stock Option Activities) (Details)", "shortName": "Stockholders' Equity (Stock Option Activities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Dw_7gsaPSkeGkMbbcSsv3w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R80": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "longName": "99941308 - Disclosure - Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details)", "shortName": "Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_kLyGBn_6oUaYv8BvCmZWAw", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_AwardTypeAxis_fbio_RestrictedStockAndRestrictedStockUnitsMember_l8RQ8CfhjEioH6WUcideLw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R81": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails", "longName": "99941309 - Disclosure - Stockholders' Equity (Schedule of Warrant activities) (Details)", "shortName": "Stockholders' Equity (Schedule of Warrant activities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Dw_7gsaPSkeGkMbbcSsv3w", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:ClassOfWarrantOrRightNumberOfSharesGranted", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R82": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails", "longName": "99941310 - Disclosure - Stockholders' Equity (Weighted average Significant Unobservable Inputs) (Details)", "shortName": "Stockholders' Equity (Weighted average Significant Unobservable Inputs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_krPTOBh_oki93SepeZkTWw", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_ATZa30MH5EafYTxEqDv5fg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_fbio_OaktreeWarrants2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_hHkB9WMB8EiM6iB9H16Wqg", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_ATZa30MH5EafYTxEqDv5fg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R83": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "longName": "99941311 - Disclosure - Stockholders' Equity (LTIP) (Details)", "shortName": "Stockholders' Equity (LTIP) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_fbio_LongTermIncentivePlanMember_mboJpvNkEk-vZBiv7TpgEA", "name": "fbio:LongTermIncentiveProgramPercentageOfOutstandingShares", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "fbio:LongTermIncentiveProgramPercentageOfOutstandingShares", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R84": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "longName": "99941312 - Disclosure - Stockholders' Equity (Capital Raises) (Narrative) (Details)", "shortName": "Stockholders' Equity (Capital Raises) (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:ProceedsFromWarrantExercises", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_1_2024_To_9_30_2024_VoRkqLodnEivYHG_eOM0Lw", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R85": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "longName": "99941313 - Disclosure - Stockholders' Equity (Narrative) (Details)", "shortName": "Stockholders' Equity (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_fbio_TwoThousandTwelveEmployeeStockPurchasePlanMember_yvlGzKTlSUequYtn-2DZkA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R86": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "longName": "99941401 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "shortName": "Commitments and Contingencies (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:GainLossOnTerminationOfLease", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R87": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails", "longName": "99941402 - Disclosure - Commitments and Contingencies (Lease Expense) (Details)", "shortName": "Commitments and Contingencies (Lease Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails", "longName": "99941403 - Disclosure - Commitments and Contingencies (Quantitative Information about Operating Leases) (Details)", "shortName": "Commitments and Contingencies (Quantitative Information about Operating Leases) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:LesseeLeasePortfolioAndOtherSupplementalLeaseInformation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:LesseeLeasePortfolioAndOtherSupplementalLeaseInformation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails", "longName": "99941404 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)", "shortName": "Commitments and Contingencies (Future Minimum Lease Payments) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.fortressbiotech.com/role/DisclosureEmployeeBenefitPlanDetails", "longName": "99941501 - Disclosure - Employee Benefit Plan (Details)", "shortName": "Employee Benefit Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "longName": "99941601 - Disclosure - Related Party Transactions (Narrative) (Details)", "shortName": "Related Party Transactions (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:PreferredStockLiquidationPreference", "unitRef": "Unit_Divide_USD_shares_ATZa30MH5EafYTxEqDv5fg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:PreferredStockLiquidationPreference", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2020_To_8_31_2020_srt_CounterpartyNameAxis_fbio_CypriumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_DcrTthXv50-GaD1jNxvtNg", "name": "fbio:SharesExchangedForCash", "unitRef": "Unit_Standard_shares_GrBwRp_5S0mEfqs_EWe9Qg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R92": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "longName": "99941602 - Disclosure - Related Party Transactions (Schedule of Equity Fees) (Details)", "shortName": "Related Party Transactions (Schedule of Equity Fees) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:DividendsReceivable", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:DividendsReceivable", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "longName": "99941603 - Disclosure - Related Party Transactions (Management Services Agreement) (Details)", "shortName": "Related Party Transactions (Management Services Agreement) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:AnnualManagementServicesAgreementFeeIncome", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:AnnualManagementServicesAgreementFeeIncome", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "longName": "99941604 - Disclosure - Related Party Transactions (Board Services Agreement) (Details)", "shortName": "Related Party Transactions (Board Services Agreement) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "Duration_12_1_2016_To_12_31_2016_srt_ConsolidatedEntitiesAxis_fbio_CheckpointMember_srt_CounterpartyNameAxis_fbio_CaribeBioadvisorsMember_us-gaap_RelatedPartyTransactionAxis_fbio_BoardServicesAgreementMember_3wy1-RzFO0u7BnO5lkfuBQ", "name": "us-gaap:ProfessionalFees", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_12_1_2016_To_12_31_2016_srt_ConsolidatedEntitiesAxis_fbio_CheckpointMember_srt_CounterpartyNameAxis_fbio_CaribeBioadvisorsMember_us-gaap_RelatedPartyTransactionAxis_fbio_BoardServicesAgreementMember_3wy1-RzFO0u7BnO5lkfuBQ", "name": "us-gaap:ProfessionalFees", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "longName": "99941605 - Disclosure - Related Party Transactions (Avenue Subscription and Forgiveness Agreement) (Details)", "shortName": "Related Party Transactions (Avenue Subscription and Forgiveness Agreement) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_kLyGBn_6oUaYv8BvCmZWAw", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_11_13_2024_srt_ConsolidatedEntitiesAxis_fbio_AvenueTherapeuticsIncMember_us-gaap_RelatedPartyTransactionAxis_fbio_AvenueSubscriptionAndForgivenessAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_4b2DgYU1z0CmsePS8JE09A", "name": "fbio:PercentageOfAmountOwedConvertedIntoShares", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R96": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "longName": "99941701 - Disclosure - Income taxes (Narrative) (Details)", "shortName": "Income taxes (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "fbio:MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn", "unitRef": "Unit_Standard_pure_imljVBmAHUeLb6J6_igJ_w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails", "longName": "99941702 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit) (Details)", "shortName": "Income Taxes (Components of Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "longName": "99941703 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)", "shortName": "Income Taxes (Deferred Tax Assets and Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "longName": "99941704 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)", "shortName": "Income Taxes (Effective Income Tax Rate Reconciliation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails", "longName": "99941705 - Disclosure - Income Taxes (Reconciliation of unrecognized tax benefits) (Details)", "shortName": "Income Taxes (Reconciliation of unrecognized tax benefits) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Dw_7gsaPSkeGkMbbcSsv3w", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R101": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails", "longName": "99941706 - Disclosure - Income Taxes (Income taxes paid (net of refunds received) by jurisdiction) (Details)", "shortName": "Income Taxes (Income taxes paid (net of refunds received) by jurisdiction) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "longName": "99941801 - Disclosure - Segment Information (Schedule of Segment Information) (Details)", "shortName": "Segment Information (Schedule of Segment Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_kLyGBn_6oUaYv8BvCmZWAw", "name": "fbio:LossRecoveryOfCosts", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R103": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "longName": "99941901 - Disclosure - Revenues from Contracts and Significant Customers (Company's product revenue) (Details)", "shortName": "Revenues from Contracts and Significant Customers (Company's product revenue) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_fbio_EmrosiMember_1Znry7kpykaXXTnxvfa0OA", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R104": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "longName": "99941902 - Disclosure - Revenues from Contracts and Significant Customers (Narrative) (Details)", "shortName": "Revenues from Contracts and Significant Customers (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_Mux0DpYSRUKC_sLINgdw-A", "name": "us-gaap:OtherIncome", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_StatementBusinessSegmentsAxis_fbio_DermatologyProductsSalesMember_f2O7zJI1oUmQlvqV-5210A", "name": "fbio:NumberOfCustomers", "unitRef": "Unit_Standard_customer_kvrDM_FJAUaUX189iNd-1g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "fbio:NumberOfCustomers", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } }, "R105": { "role": "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "longName": "99942001 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "As_Of_12_31_2025_zjz4eitsk0uD91QVapfNDg", "name": "us-gaap:PreferredStockLiquidationPreference", "unitRef": "Unit_Divide_USD_shares_ATZa30MH5EafYTxEqDv5fg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:PreferredStockLiquidationPreference", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_2_22_2026_srt_StatementScenarioAxis_fbio_ReductionInDebtCovenantMember_us-gaap_DebtInstrumentAxis_fbio_SecondAmendmentAgreementMember_GkPHTRhj20mFWW73gSZZag", "name": "fbio:DebtInstrumentCovenantMinimumLiquidityAmount", "unitRef": "Unit_Standard_USD_UvvvBbca-UCyOnSMT_U4uw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20251231x10k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "fbio_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "fbio_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccountingPoliciesTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Table]", "label": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Company owed amount", "verboseLabel": "Other receivables", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "fbio_AccountsPayableAndAccruedExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccountsPayableAndAccruedExpensesLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table.", "label": "Accounts Payable and Accrued Expenses [Line Items]" } } }, "auth_ref": [] }, "fbio_AccountsPayableAndAccruedExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccountsPayableAndAccruedExpensesTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Presentation of information about accounts payable and accrued expenses.", "label": "Accounts Payable and Accrued Expenses [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r57", "r58" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accounts Payable and Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r55", "r58", "r64", "r1490" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r55", "r1155" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsReceivableMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r1019", "r1409" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1418" ] }, "fbio_AccretionOfPartnerCompanyConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccretionOfPartnerCompanyConvertiblePreferredShares", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Accretion of partner company convertible preferred shares.", "label": "Accretion of partner company convertible preferred shares", "terseLabel": "Accretion of partner company convertible preferred shares" } } }, "auth_ref": [] }, "fbio_AccruedCouponExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccruedCouponExpenseCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued coupon expense which is classified as current.", "label": "Accrued Coupon Expense Current", "verboseLabel": "Accrued coupon and rebates" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Total accounts payable and accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r58" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses:" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r58" ] }, "fbio_AccruedResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccruedResearchAndDevelopmentExpense", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Research and Development Expense", "label": "Accrued Research And Development Expense", "verboseLabel": "Research and development" } } }, "auth_ref": [] }, "fbio_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for expected cost of research, preclinical, clinical and manufacturing development.", "label": "Accrued Research And Development Expense, Policy [Policy Text Block]", "terseLabel": "Accrued Research and Development Expense" } } }, "auth_ref": [] }, "fbio_AccruedReturnReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccruedReturnReserveCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued return reserve, current.", "label": "Accrued Return Reserve Current", "terseLabel": "Return reserve" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r58", "r1043" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Salaries, Current", "verboseLabel": "Salaries, bonus and related benefits", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r58", "r1043" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r31", "r151", "r853" ] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Distributions in Excess of Net Income [Member]", "verboseLabel": "Accumulated Deficit", "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings)." } } }, "auth_ref": [] }, "fbio_AccutaneLicenseAndSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccutaneLicenseAndSupplyAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Accutane license and supply agreement", "label": "Accutane License And Supply Agreement [Member]", "terseLabel": "Accutane" } } }, "auth_ref": [] }, "fbio_AccutaneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AccutaneMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Accutane [Member]", "label": "Accutane" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r1243" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r69", "r1155", "r1590" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r915", "r1400", "r1401", "r1402", "r1403", "r1524", "r1596" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1256" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r1256" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1256" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1256" ] }, "fbio_AdjustmentForWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentForWarrants", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from adjustment for warrants.", "label": "Adjustment For Warrants", "terseLabel": "Adjustment for warrants" } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease/increase in additional paid in capital (APIC) and non controlling interest in subsidiaries.", "label": "Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance", "negatedLabel": "Changes in non-controlling interest in subsidiaries" } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of common stock.", "label": "Adjustments To Additional Paid In Capital Dividends In Excess Of Common Stock", "negatedLabel": "Partner company's dividends declared and paid" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings", "negatedLabel": "Preferred A dividends declared and paid", "verboseLabel": "Preferred Stock dividends", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": [ "r11", "r106" ] }, "fbio_AdjustmentsToAdditionalPaidInCapitalExchangeOfPartnerCompanyPreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalExchangeOfPartnerCompanyPreferredShares", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from exchange of partner company preferred shares.", "label": "Adjustments To Additional Paid In Capital, Exchange Of Partner Company Preferred Shares", "terseLabel": "Exchange of partner company preferred shares" } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalExerciseOfPartnerCompanyOptionsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfPartnerCompanyOptionsAndWarrants", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the exercise of partner company options and warrants.", "label": "Adjustments to Additional Paid in Capital, Exercise of Partner Company Options and Warrants", "terseLabel": "Exercise of partner company options and warrants for cash, net" } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalPartnerCompaniesOfferingsNetAndWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalPartnerCompaniesOfferingsNetAndWarrantExercises", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from offerings, net and warrant exercises.", "label": "Adjustments to Additional Paid in Capital, Partner Companies Offerings, Net and Warrant Exercises", "terseLabel": "Partner companies' offerings, net and warrant exercises" } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPartnerCompanyPreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfPartnerCompanyPreferredShares", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of partner company preferred shares to liability.", "label": "Adjustments To Additional Paid In Capital, Reclassification Of Partner Company Preferred Shares", "terseLabel": "Reclass to liabilities for partner company perpetual preferred" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [ "r459", "r546" ] }, "fbio_AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from subsidiary's at market offering costs.", "label": "Adjustments To Additional Paid In Capital Subsidiary At Market Offering", "verboseLabel": "Partner companies' at-the-market offering, net" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation of net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "fbio_AevitasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AevitasMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Aevitas [Member]", "terseLabel": "Aevitas" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1301" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1214", "r1225", "r1235", "r1268" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r1217", "r1228", "r1238", "r1271" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1302" ] }, "fbio_AgreementWithPartnerCompaniesChangeInControlFeeDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AgreementWithPartnerCompaniesChangeInControlFeeDescription", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of change in control, under the agreement with partner companies.", "label": "Agreement With Partner Companies, Change in Control Fee, Description", "terseLabel": "Agreement with partner companies, change in control, description" } } }, "auth_ref": [] }, "fbio_AgreementWithPartnerCompaniesPercentageOfAnnualNetAssetsPayableAsCashFee": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AgreementWithPartnerCompaniesPercentageOfAnnualNetAssetsPayableAsCashFee", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of annual cash fee payable, under the agreement with partner companies.", "label": "Agreement With Partner Companies, Percentage of Annual Net Assets Payable as Cash Fee", "terseLabel": "Percentage of cash fee payable" } } }, "auth_ref": [] }, "fbio_AgreementWithPartnerCompaniesPercentageOfGrossAmountOfAnySuchEquityOrDebtFinancing": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AgreementWithPartnerCompaniesPercentageOfGrossAmountOfAnySuchEquityOrDebtFinancing", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of gross amount of any equity or debt financing, under the agreement with partner companies.", "label": "Agreement With Partner Companies, Percentage of Gross Amount of any Such Equity or Debt Financing", "terseLabel": "Percentage of gross amount of any equity or debt financing" } } }, "auth_ref": [] }, "fbio_AgreementWithPartnerCompaniesPercentageOfStockOwned": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AgreementWithPartnerCompaniesPercentageOfStockOwned", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of stock owned, under the agreement with partner companies.", "label": "Agreement With Partner Companies, Percentage of Stock Owned", "terseLabel": "Percentage of Founders Stock owned" } } }, "auth_ref": [] }, "fbio_AgreementWithPartnerCompaniesPeriodForPaymentOfAnnualCashFee": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AgreementWithPartnerCompaniesPeriodForPaymentOfAnnualCashFee", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period for payment of annual cash fee, under the agreement with partner companies.", "label": "Agreement With Partner Companies, Period for Payment of Annual Cash Fee", "terseLabel": "Period for payment of annual cash fee" } } }, "auth_ref": [] }, "fbio_AgreementWithPartnerCompaniesPeriodForPaymentOfEquityFees": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AgreementWithPartnerCompaniesPeriodForPaymentOfEquityFees", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period for payment of equity fees, under the agreement with partner companies.", "label": "Agreement With Partner Companies, Period for Payment of Equity Fees", "terseLabel": "Period for payment of equity fees" } } }, "auth_ref": [] }, "fbio_AgreementWithPartnerCompaniesTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AgreementWithPartnerCompaniesTerm", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement with partner companies, term", "label": "Agreement With Partner Companies, Term", "terseLabel": "Agreement with partner companies, term" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r1256" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1263" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1263", "r1272", "r1276", "r1284" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1282" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r532", "r536", "r545" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss", "verboseLabel": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r159", "r290", "r329", "r332", "r334", "r1557" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r6", "r84", "r431", "r1538" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails": { "parentTag": "fbio_InterestExpenseTotalNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of fees", "verboseLabel": "Issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r84", "r431", "r1387", "r1538" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of acquired intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets." } } }, "auth_ref": [ "r6", "r178", "r357", "r365", "r1040", "r1047", "r1048", "r1050", "r1052" ] }, "fbio_AnnualCashDividendPerSharePayable": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualCashDividendPerSharePayable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual cash dividend payable per share.", "label": "Annual Cash Dividend Per Share Payable", "terseLabel": "Annual cash dividend payable" } } }, "auth_ref": [] }, "fbio_AnnualConsultingFeePayableEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualConsultingFeePayableEffectiveDate", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Date the consulting fee to be paid.", "label": "Annual Consulting Fee Payable Effective Date", "verboseLabel": "Effective date" } } }, "auth_ref": [] }, "fbio_AnnualEquityFeeAsPercentageOfFullyDilutedOutstandingCapitalization": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualEquityFeeAsPercentageOfFullyDilutedOutstandingCapitalization", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual equity fee as a percentage of fully diluted outstanding capitalization", "label": "Annual equity fee as a percentage of fully diluted outstanding capitalization" } } }, "auth_ref": [] }, "fbio_AnnualManagementServicesAgreementFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualManagementServicesAgreementFeeExpense", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual Management Services Agreement Fee expense.", "label": "Annual Management Services Agreement Fee expense", "terseLabel": "Partner companies, MSA fee expense" } } }, "auth_ref": [] }, "fbio_AnnualManagementServicesAgreementFeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualManagementServicesAgreementFeeIncome", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual Management Services Agreement Fee Income", "label": "Annual Management Services Agreement Fee Income", "negatedLabel": "Fortress - MSA Income" } } }, "auth_ref": [] }, "fbio_AnnualManagementServicesAgreementFeeIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualManagementServicesAgreementFeeIncomeExpense", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of (income)expense related to annual management services agreement fee.", "label": "Annual Management Services Agreement Fee Income expense", "terseLabel": "Consolidated (Income)/Expense" } } }, "auth_ref": [] }, "fbio_AnnualNetSalesBetween75MillionAnd100MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualNetSalesBetween75MillionAnd100MillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to annual net sales between $75 million and $100 million.", "label": "Annual Net Sales Between $75 Million And $100 Million [Member]", "terseLabel": "Annual net sales between $75 million and $100 million" } } }, "auth_ref": [] }, "fbio_AnnualNetSalesInExcessOf100MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualNetSalesInExcessOf100MillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to annual net sales in excess of $100 million.", "label": "Annual Net Sales In Excess Of $100 Million [Member]", "terseLabel": "Annual net sales in excess of $100 million" } } }, "auth_ref": [] }, "fbio_AnnualNetSalesUpTo75MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualNetSalesUpTo75MillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to annual net sales up to $75 million.", "label": "Annual Net Sales Up to 75 Million [Member]", "terseLabel": "Annual net sales up to $75 million" } } }, "auth_ref": [] }, "fbio_AnnualNetSalesUsedAsBasisForMilestonesPayableLicensingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualNetSalesUsedAsBasisForMilestonesPayableLicensingAgreements", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of annual net sales used as the basis for milestones payable under license agreement.", "label": "Annual Net Sales Used As Basis For Milestones Payable, Licensing Agreements", "terseLabel": "Annual net sales as basis for milestone payments" } } }, "auth_ref": [] }, "fbio_AnnualSalesOfFiveHundredMillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualSalesOfFiveHundredMillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual sales of $500 million.", "label": "Annual Sales Of $500 Million [Member]", "terseLabel": "Annual Sales Of $500 Million" } } }, "auth_ref": [] }, "fbio_AnnualSalesOfFourHundredMillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualSalesOfFourHundredMillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual sales of $400 million.", "label": "Annual Sales Of $400 Million [Member]", "terseLabel": "Annual Sales Of $400 Million" } } }, "auth_ref": [] }, "fbio_AnnualSalesOfOneHundredMillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualSalesOfOneHundredMillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual sales of $100 million.", "label": "Annual Sales Of $100 Million [Member]", "terseLabel": "Annual Sales Of $100 Million" } } }, "auth_ref": [] }, "fbio_AnnualSalesOfThreeHundredMillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualSalesOfThreeHundredMillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual sales of $300 million.", "label": "Annual Sales Of $300 Million [Member]", "terseLabel": "Annual Sales Of $300 Million" } } }, "auth_ref": [] }, "fbio_AnnualSalesOfTwoHundredMillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AnnualSalesOfTwoHundredMillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual sales of $200 million.", "label": "Annual Sales Of $200 Million [Member]", "terseLabel": "Annual Sales Of $200 Million" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r228" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r228" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r228" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r228" ] }, "fbio_AreaOfLandOperatingSublease": { "xbrltype": "areaItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AreaOfLandOperatingSublease", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the area of property subject to operating sublease.", "label": "Area of land, Operating Sublease", "terseLabel": "Area of land" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r655" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r354", "r358", "r359", "r360", "r361", "r363", "r896", "r1516" ] }, "fbio_AssetAcquisitionConsiderationInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionConsiderationInCash", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash consideration to be transferred in asset acquisition.", "label": "Asset Acquisition Consideration In Cash", "verboseLabel": "Purchase price" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionConsiderationSubsequentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionConsiderationSubsequentPayment", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of subsequent payment for asset acquisition consideration.", "label": "Asset Acquisition Consideration, Subsequent Payment", "terseLabel": "Subsequent amount" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionConsiderationSubsequentPaymentDuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionConsiderationSubsequentPaymentDuePeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period when subsequent payment for asset acquisition becomes due.", "label": "Asset Acquisition Consideration, Subsequent Payment, Due Period", "terseLabel": "Subsequent payment due period" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionConsiderationSubsequentPaymentExtendedDuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionConsiderationSubsequentPaymentExtendedDuePeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Extended Period for subsequent payment for asset acquisition due.", "label": "Asset Acquisition Consideration, Subsequent Payment, Extended Due Period", "terseLabel": "Subsequent payment extended due period" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionConsiderationThresholdNetAssetsConsideredForDelayInSubsequentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionConsiderationThresholdNetAssetsConsideredForDelayInSubsequentPayment", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold amount of net assets considered for delay in payment of deferred amount under the asset acquisition transaction.", "label": "Asset Acquisition Consideration, Threshold Net Assets Considered For Delay In Subsequent Payment", "terseLabel": "Asset acquisition consideration, threshold net assets considered for delay in subsequent payment" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1135", "r1517", "r1518", "r1519" ] }, "fbio_AssetAcquisitionConsiderationTransferredInExcessOfFairValueOfAssetsAllocatedToSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionConsiderationTransferredInExcessOfFairValueOfAssetsAllocatedToSupplies", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of consideration in excess of fair value of the asset allocated to supplies repurchased.", "label": "Asset Acquisition, Consideration Transferred, in Excess of Fair Value of Assets, Allocated to Supplies", "verboseLabel": "Fair value of supplies received by partner company expensed to research and development" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionConsiderationUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionConsiderationUpfrontPayment", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront payment for asset acquisition consideration.", "label": "Asset Acquisition Consideration, Upfront Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r354", "r358", "r359", "r360", "r361", "r363", "r896", "r1516" ] }, "fbio_AssetAcquisitionFuturePaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionFuturePaymentsDue", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the undiscounted value of future cash payments due in an asset acquisition.", "label": "Asset Acquisition, Future Payments Due", "terseLabel": "Deferred cash payment" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionInterestRateOnOutstandingLiability": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionInterestRateOnOutstandingLiability", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents percentage of interest accrual on outstanding liability in asset acquisition transaction.", "label": "Asset Acquisition, Interest Rate on Outstanding Liability", "terseLabel": "Interest rate on outstanding liability" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionPercentageOfCommonStockIssued": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetAcquisitionPercentageOfCommonStockIssued", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock issued to the company, pursuant to asset acquisition arrangement.", "label": "Asset Acquisition, Percentage Of Common Stock Issued", "terseLabel": "Percentage of equity to be held" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "terseLabel": "Asset impairment", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r6", "r29", "r1165", "r1166" ] }, "fbio_AssetPurchaseRoyaltyAndRelatedAgreementsWithCrystalisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetPurchaseRoyaltyAndRelatedAgreementsWithCrystalisMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to asset purchase, royalty and related agreements with Crystalis.", "label": "Asset Purchase, Royalty And Related Agreements With Crystalis [Member]", "terseLabel": "Asset Purchase, Royalty And Related Agreements With Crystalis" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "terseLabel": "Segment assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r111", "r122", "r154", "r188", "r191", "r192", "r233", "r247", "r273", "r277", "r326", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r657", "r663", "r710", "r831", "r832", "r842", "r953", "r1066", "r1067", "r1081", "r1155", "r1175", "r1177", "r1192", "r1445", "r1446", "r1547" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "fbio_AssetsAcquisitionNumberOfDaysToAssumeControlOverDevelopmentOfCutx101": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetsAcquisitionNumberOfDaysToAssumeControlOverDevelopmentOfCutx101", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained by period end date.", "label": "Assets Acquisition Number Of Days To Assume Control Over Development Of Cutx 101", "terseLabel": "Number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r146", "r162", "r188", "r191", "r192", "r326", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r657", "r663", "r710", "r1155", "r1445", "r1446", "r1547" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "fbio_AssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetsHeldForSale", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount representing assets held for sale.", "label": "Assets Held For Sale", "terseLabel": "Assets held for sale" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "verboseLabel": "Assets held for sale", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r98", "r1155" ] }, "fbio_AssetsHeldForSalePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetsHeldForSalePolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for assets held for sale.", "label": "Assets Held For Sale Policy Text Block", "terseLabel": "Assets Held for Sale" } } }, "auth_ref": [] }, "fbio_AssetsSoldUnderAgreementsToRepurchaseAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AssetsSoldUnderAgreementsToRepurchaseAccretionExpense", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accretion expense recognized under assets sold under repurchase agreements for the passage of time, typically for liabilities, that have been discounted to their net present values.", "label": "Assets Sold under Agreements to Repurchase, Accretion Expense" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1197", "r1198", "r1221" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r1197", "r1198", "r1221" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r1197", "r1198", "r1221" ] }, "fbio_AvenueShareRepurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AvenueShareRepurchaseAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Avenue Share Repurchase Agreement.", "label": "Avenue Share Repurchase Agreement [Member]", "terseLabel": "Avenue Share Repurchase Agreement" } } }, "auth_ref": [] }, "fbio_AvenueSubscriptionAndForgivenessAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AvenueSubscriptionAndForgivenessAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Information relating to the Avenue subscription and forgiveness agreement.", "label": "Avenue Subscription and Forgiveness Agreement [Member]", "terseLabel": "Avenue Subscription and Forgiveness Agreement" } } }, "auth_ref": [] }, "fbio_AvenueTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "AvenueTherapeuticsIncMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Avenue Therapeutics, Inc.", "label": "Avenue Therapeutics, Inc [Member]", "terseLabel": "Avenue" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1279" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1280" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1275" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1275" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r1275" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1275" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1275" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1275" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r528", "r529", "r530", "r531" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1278" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1277" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1276" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1276" ] }, "fbio_BaergicMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "BaergicMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Baergic [Member]", "terseLabel": "Baergic" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation and Principles of Consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1390" ] }, "fbio_BoardServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "BoardServicesAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Information relating to the board services agreement.", "label": "Board Services Agreement [Member]", "terseLabel": "Board services agreement" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BuildingMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Building [Member]", "terseLabel": "Buildings", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r99" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r354", "r358", "r359", "r360", "r361", "r363", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r896", "r1096", "r1097", "r1511", "r1514", "r1515" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r354", "r358", "r359", "r360", "r361", "r363", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r896", "r1096", "r1097", "r1511", "r1514", "r1515" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r354", "r598", "r599", "r600", "r601", "r607", "r608", "r609", "r610", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r645", "r646", "r647", "r650", "r1103", "r1106", "r1511", "r1514", "r1515" ] }, "fbio_CaribeBioadvisorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CaribeBioadvisorsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Caribe BioAdvisors", "label": "Caribe BioAdvisors [Member]", "terseLabel": "Caribe" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r19", "r149", "r1041" ] }, "fbio_CashAndCashEquivalentsParentCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CashAndCashEquivalentsParentCompany", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits for the parent company. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents, Parent Company" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r20" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r20", "r110" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash and cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r19", "r91", "r185" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1", "r91" ] }, "fbio_CellvationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CellvationMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Cellvation [Member]", "terseLabel": "Cellvation" } } }, "auth_ref": [] }, "fbio_ChangeInFairValueOfContingentlyIssuableWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ChangeInFairValueOfContingentlyIssuableWarrants", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to change in fair value of contingently issuable warrants.", "label": "Change In Fair Value Of Contingently Issuable Warrants", "terseLabel": "Change in fair value of partner companies' warrant liabilities" } } }, "auth_ref": [] }, "fbio_ChangeOfControlMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ChangeOfControlMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "documentation": "Change of Control [Member]", "label": "Change of Control [Member]", "terseLabel": "Change of Control" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r1254" ] }, "fbio_CheckpointMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CheckpointMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Checkpoint.", "label": "Checkpoint [Member]", "terseLabel": "Checkpoint Merger", "verboseLabel": "Checkpoint" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer (Dr. Rosenwald)" } } }, "auth_ref": [ "r1417" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r1251" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r1249" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r136", "r156", "r157", "r158", "r188", "r192", "r221", "r222", "r225", "r227", "r235", "r236", "r326", "r398", "r401", "r402", "r403", "r407", "r408", "r442", "r443", "r445", "r446", "r448", "r451", "r453", "r454", "r456", "r457", "r459", "r710", "r904", "r905", "r906", "r907", "r915", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r941", "r961", "r984", "r1008", "r1009", "r1010", "r1011", "r1012", "r1307", "r1393", "r1395", "r1404" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1455" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right Exercisable.", "label": "Class Of Warrant Or Right Exercisable", "terseLabel": "Warrants Exercisable, Number of shares" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right exercisable, Weighted Average Exercise Price", "label": "Class Of Warrant Or Right exercisable, Weighted Average Exercise Price", "terseLabel": "Warrants Exercisable, Weighted average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right exercisable, Weighted average intrinsic value", "label": "Class of Warrant or Right exercisable, Weighted average intrinsic value", "terseLabel": "Warrants Exercisable, Total weighted average intrinsic value" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right exercisable, Weighted Average remaining contractual life", "label": "Class Of Warrant Or Right exercisable, Weighted Average remaining contractual life", "terseLabel": "Warrants exercisable, Weighted average remaining contractual life" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Cash payment per share", "verboseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r188", "r194", "r460" ] }, "fbio_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAgreedByInvestor": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAgreedByInvestor", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights agreed by investor.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights Agreed by Investor", "verboseLabel": "Exercise price of warrants agreed by investor" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right Exercised Weighted Average Exercise Price", "label": "Class Of Warrant Or Right Exercised Weighted Average Exercise Price", "terseLabel": "Warrants Exercised, Weighted average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right granted, Weighted average exercise price", "label": "Class of Warrant or Right granted, Weighted average exercise price", "terseLabel": "Warrants Issued, Weighted average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right granted, Weighted average intrinsic value.", "label": "Class of Warrant or Right granted, Weighted average intrinsic value", "terseLabel": "Warrants Issued, Total weighted average intrinsic value" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "verboseLabel": "Number of shares called by warrants", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued", "verboseLabel": "Number of warrants to purchase shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r460" ] }, "fbio_ClassOfWarrantOrRightNumberOfSharesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightNumberOfSharesExercised", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Number of shares Exercised.", "label": "Warrants exercised, Number of shares", "negatedLabel": "Warrants Exercised, Number of shares", "terseLabel": "Warrants exercised, Number of shares" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightNumberOfSharesGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightNumberOfSharesGranted", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Number of shares granted.", "label": "Class Of Warrant Or Right, Number of shares granted", "terseLabel": "Warrants Issued, Number of shares" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightNumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued.", "label": "Class of Warrant or Right, Number of Warrants Issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants Outstanding, Number of shares", "periodStartLabel": "Warrants Outstanding, Number of shares", "terseLabel": "Outstanding warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "decimalItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of securities into which the class of warrant or right may be converted.", "label": "Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightWarrantsExercisedForShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightWarrantsExercisedForShares", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised for shares.", "label": "Class Of Warrant Or Right, Warrants Exercised For Shares", "terseLabel": "Class of warrant or right, warrants exercised for shares" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Weighted average exercise price", "label": "Class of Warrant or Right, Weighted average exercise price", "periodEndLabel": "Warrants Outstanding, Weighted average exercise price", "periodStartLabel": "Warrants Outstanding, Weighted average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightWeightedAverageIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightWeightedAverageIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Weighted average intrinsic value.", "label": "Class of Warrant or Right, Weighted average intrinsic value", "periodEndLabel": "Warrants Outstanding, Total weighted average intrinsic value", "periodStartLabel": "Warrants Outstanding, Total weighted average intrinsic value" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Life", "label": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Life", "periodEndLabel": "Warrants Outstanding, Weighted average remaining contractual life (years)", "periodStartLabel": "Warrants Outstanding, Weighted average remaining contractual life (years)" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightsExercisedWeightedAverageIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ClassOfWarrantOrRightsExercisedWeightedAverageIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right exercised, Weighted average intrinsic value.", "label": "Class Of Warrant Or Rights, Exercised, Weighted Average Intrinsic Value", "terseLabel": "Warrants Exercised, Total weighted average intrinsic value" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1255" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r1255" ] }, "fbio_CollaborationAndStockPurchaseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CollaborationAndStockPurchaseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Asset Purchase and Merger Agreements" } } }, "auth_ref": [] }, "fbio_CollaborationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CollaborationRevenue", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue.", "label": "Collaboration revenue", "verboseLabel": "Collaboration revenue" } } }, "auth_ref": [] }, "fbio_CollaborationrevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CollaborationrevenueMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaboration Revenue Member.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration revenue" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreements" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License Agreements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r135", "r653", "r654" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 14)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r65", "r114", "r844", "r940" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r102", "r387", "r388", "r1020", "r1432", "r1437" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies, Policy [Policy Text Block]", "verboseLabel": "Contingencies", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r32", "r1021" ] }, "fbio_CommonSharesIssuableForDividendOnPartnerCompanyConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CommonSharesIssuableForDividendOnPartnerCompanyConvertiblePreferredShares", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Common shares issuable for dividend on partner company's convertible preferred shares.", "label": "Common Shares Issuable For Dividend On Partner Company Convertible Preferred Shares", "terseLabel": "Common shares issued for dividend on partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period for dividend on partner company's convertible preferred shares.", "label": "Common shares issued for dividend on partner company's convertible preferred shares", "terseLabel": "Common shares issued for dividend on partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredSharesInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredSharesInShares", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "It represents the stock issued during period shares issued for partner company's convertible preferred shares.", "label": "Common shares issued for dividend on partner company's convertible preferred shares (in shares)" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredShares", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period for exchange of partner company's convertible preferred shares.", "label": "Common shares issued for exchange of partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredSharesInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredSharesInShares", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "It represents the stock issued during period shares issued for exchange of partner company's convertible preferred shares.", "label": "Common shares issued for exchange of partner company's convertible preferred shares (in shares)" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Number of shares available for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r68" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1182", "r1183", "r1184", "r1186", "r1187", "r1188", "r1189", "r1400", "r1401", "r1403", "r1524", "r1588", "r1596" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r68" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r68", "r941" ] }, "fbio_CommonStockSharesAvailableForFutureIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CommonStockSharesAvailableForFutureIssuanceValue", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents value of shares available for future issue.", "label": "Common Stock Shares Available For Future Issuance Value", "verboseLabel": "Amount available for future stock offerings" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r68" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r68", "r941", "r959", "r1596", "r1597" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized, 31,364,094 and 27,908,839 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r68", "r443", "r450", "r847", "r1155" ] }, "fbio_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CommonStockWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to common stock warrants.", "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrant" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1260" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1259" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1261" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1258" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureEmployeeBenefitPlan" ], "lang": { "en-us": { "role": { "label": "Compensation and Employee Benefit Plans [Text Block]", "verboseLabel": "Employee Benefit Plan", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r1458", "r1459", "r1460", "r1461" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefit Plan" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "verboseLabel": "Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r238", "r285", "r897", "r898", "r1019", "r1408", "r1409", "r1410", "r1411", "r1412" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r238", "r285", "r897", "r898", "r1019", "r1408", "r1409", "r1410", "r1411", "r1412" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r238", "r285", "r897", "r898", "r1019", "r1408", "r1409", "r1410", "r1411", "r1412" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r238", "r285", "r1408", "r1409", "r1410", "r1411", "r1412" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r238", "r285", "r897", "r898", "r1019", "r1408", "r1409", "r1410", "r1411", "r1412" ] }, "fbio_ConcurrentPrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ConcurrentPrivatePlacementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to concurrent private placement.", "label": "Concurrent Private Placement [Member]", "terseLabel": "Concurrent Private Placement" } } }, "auth_ref": [] }, "fbio_ConcurrentPrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ConcurrentPrivatePlacementWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to concurrent private placement warrants.", "label": "Concurrent Private Placement Warrants [Member]", "terseLabel": "Concurrent Private Placement Warrants" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r189", "r199", "r657", "r658", "r662", "r663", "r664", "r751", "r835", "r1026", "r1444", "r1447", "r1448" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r189", "r199", "r657", "r658", "r662", "r663", "r664", "r751", "r835", "r1026", "r1444", "r1447", "r1448" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r120", "r188", "r189", "r196", "r199", "r233", "r249", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r835", "r1066", "r1067", "r1445", "r1446" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r120", "r188", "r189", "r196", "r199", "r233", "r249", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r835", "r1066", "r1067", "r1445", "r1446" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "verboseLabel": "Reimbursement for clinical costs", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r462", "r463", "r465", "r484" ] }, "fbio_ConvertibleClassBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ConvertibleClassBPreferredStockMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Class B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Class B Preferred Stock [Member]", "terseLabel": "8% Cumulative Convertible Class B Preferred Offering" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods - (excluding amortization of acquired intangible assets)", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r79", "r80", "r792", "r1048", "r1053", "r1138", "r1380" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r86" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r188", "r197", "r198", "r413", "r455", "r749", "r771", "r840", "r1044", "r1045", "r1046", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1520", "r1521", "r1522", "r1523" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CreditFacilityAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r397", "r1443" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CreditFacilityDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r397", "r1443" ] }, "fbio_CrystalysTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CrystalysTherapeuticsIncMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Crystalys Therapeutics, Inc.", "label": "Crystalys Therapeutics, Inc [Member]", "terseLabel": "Crystalys Therapeutics, Inc" } } }, "auth_ref": [] }, "us-gaap_CumulativePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CumulativePreferredStockMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cumulative Preferred Stock [Member]", "documentation": "Preferred stock upon which unpaid dividends accumulate until paid to shareholders. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "verboseLabel": "Current" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1314", "r1391", "r1397", "r1505" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "verboseLabel": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1314", "r1391", "r1397", "r1505" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r285", "r1409" ] }, "fbio_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CustomerTwoMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer Two [Member]", "label": "Customer Two" } } }, "auth_ref": [] }, "fbio_CutiaTherapeuticsHkLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CutiaTherapeuticsHkLimitedMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Cutia Therapeutics (HK) Limited (\"Cutia\").", "label": "Cutia Therapeutics (HK) Limited [Member]", "terseLabel": "Cutia Therapeutics (HK) Limited" } } }, "auth_ref": [] }, "fbio_CybersecurityIncidentAmountTransferredToFraudulentAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CybersecurityIncidentAmountTransferredToFraudulentAccounts", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount wrongly misdirected to a fraudulent accounts due to cybersecurity incident from business email compromise.", "label": "Cybersecurity Incident, Amount Transferred To Fraudulent Accounts", "terseLabel": "Cybersecurity incident amount transferred to fraudulent accounts" } } }, "auth_ref": [] }, "fbio_CybersecurityIncidentRecoveryOfPortionOfFundsTransferredEarlierToFraudulentAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CybersecurityIncidentRecoveryOfPortionOfFundsTransferredEarlierToFraudulentAccounts", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Portion of the fraudulent transferred amount earlier due to cybersecurity incident recovered and received by the company during the period.", "label": "Cybersecurity Incident, Recovery Of Portion Of Funds Transferred Earlier To Fraudulent Accounts", "terseLabel": "Cybersecurity incident recovered funds" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1206", "r1295" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1206", "r1295" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1208", "r1297" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1208", "r1297" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1210", "r1299" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1208", "r1297" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1201", "r1290" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1202", "r1291" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1202", "r1291" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1200", "r1289" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1200", "r1289" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1200", "r1289" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1203", "r1292" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1205", "r1294" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1205", "r1294" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1206", "r1295" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1209", "r1298" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1207", "r1296" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1204", "r1293" ] }, "fbio_CypriumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "CypriumMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Cyprium Therapeutics, Inc.", "label": "Cyprium [Member]", "terseLabel": "Cyprium" } } }, "auth_ref": [] }, "fbio_DebtCovenantNoLongerApplyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtCovenantNoLongerApplyMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to scenario in which there is no debt covenants.", "label": "Debt Covenant No Longer Apply [Member]", "terseLabel": "Debt covenant no longer apply" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt and Interest" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterest" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt and Interest", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r103", "r188", "r190", "r378", "r379", "r380", "r381", "r382", "r396", "r397", "r409", "r415", "r416", "r417", "r418", "r419", "r420", "r425", "r432", "r433", "r435", "r669", "r722" ] }, "fbio_DebtInstrumentAggregateCommonEquityOrCashDistributionsToBeReceivedAsPercentageOfAmountSetForthInAnnualBudget": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentAggregateCommonEquityOrCashDistributionsToBeReceivedAsPercentageOfAmountSetForthInAnnualBudget", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold amount of aggregate common equity or cash distributions to be received as per the debt agreement, as a percentage of amount set forth in annual budget delivered to the Lenders.", "label": "Debt Instrument, Aggregate Common Equity or Cash Distributions to be Received, As A Percentage of Amount Set Forth In Annual Budget", "terseLabel": "Percentage of amount set forth in annual budget" } } }, "auth_ref": [] }, "fbio_DebtInstrumentAggregateOfPrincipalPrepaymentAmountInMultiples": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentAggregateOfPrincipalPrepaymentAmountInMultiples", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate of prepayment of principal amount of loans to be paid in multiples at time of the happening of certain circumstances.", "label": "Debt Instrument, Aggregate of Principal Prepayment Amount in Multiples", "terseLabel": "Debt instrument, aggregate of principal prepayment amount in multiples" } } }, "auth_ref": [] }, "fbio_DebtInstrumentAggregateOfPrincipalPrepaymentAmountMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentAggregateOfPrincipalPrepaymentAmountMinimum", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate of minimum principal amount of loans to be prepaid at the happening of certain circumstances.", "label": "Debt Instrument, Aggregate of Principal Prepayment Amount, Minimum", "terseLabel": "Debt instrument, aggregate of principal prepayment amount, minimum" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r57", "r58", "r112", "r113", "r410", "r411", "r412", "r413", "r414", "r416", "r421", "r422", "r423", "r424", "r426", "r427", "r428", "r429", "r430", "r431", "r1076", "r1077", "r1078", "r1079", "r1080", "r1153", "r1391", "r1392", "r1394", "r1399", "r1433", "r1434", "r1435", "r1537", "r1539", "r1555" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "fbio_DebtInstrumentCapRate": { "xbrltype": "pureItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentCapRate", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents variable interest cap rate of debt.", "label": "Debt Instrument, Cap Rate", "terseLabel": "Debt instrument, cap rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Outstanding amount", "verboseLabel": "Total notes payable, gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r14", "r113", "r436" ] }, "fbio_DebtInstrumentCovenantMinimumLiquidityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentCovenantMinimumLiquidityAmount", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of minimum of liquidity amount required to be maintained as per debt agreement.", "label": "Debt Instrument, Covenant, Minimum Liquidity Amount", "terseLabel": "Minimum liquidity amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r410", "r722", "r723", "r1077", "r1078", "r1153" ] }, "fbio_DebtInstrumentFloorRate": { "xbrltype": "pureItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentFloorRate", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents variable interest floor rate of debt.", "label": "Debt Instrument, Floor Rate", "terseLabel": "Debt instrument, floor rate" } } }, "auth_ref": [] }, "fbio_DebtInstrumentInterestOnlyPeriodExtendedPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentInterestOnlyPeriodExtendedPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Extended interest only period under the debt instrument.", "label": "Debt Instrument, Interest Only Period, Extended Period", "terseLabel": "Debt instrument, interest only period, extended period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "verboseLabel": "Debt, effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r60", "r438", "r722", "r723", "r1153" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r60", "r411" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt and Interest", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r416", "r421", "r422", "r423", "r424", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r669", "r835", "r1076", "r1077", "r1078", "r1079", "r1080", "r1153", "r1391", "r1392", "r1394", "r1399", "r1537", "r1539" ] }, "fbio_DebtInstrumentMandatoryPrepaymentExcessProceedsFromAnyOfCompanySSubsidiariesOtherThanInConnectionWithCertainMonetizationEvents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentMandatoryPrepaymentExcessProceedsFromAnyOfCompanySSubsidiariesOtherThanInConnectionWithCertainMonetizationEvents", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of excess proceeds from receipt of any dividend or other distributions in cash from any of the company's subsidiaries other than in connection with certain monetization events, that should be used for mandatory prepayment of debt instrument.", "label": "Debt Instrument, Mandatory Prepayment, Excess Proceeds From Any Of Company's Subsidiaries Other Than In Connection With Certain Monetization Events", "terseLabel": "Excess proceeds from any of company's subsidiaries other than in connection with certain monetization events" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentMaturityDateDescription", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date, Description", "verboseLabel": "Maturity Date, description", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": [ "r61" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r14", "r410", "r411", "r412", "r413", "r414", "r416", "r421", "r422", "r423", "r424", "r426", "r427", "r428", "r429", "r430", "r431", "r1076", "r1077", "r1078", "r1079", "r1080", "r1153", "r1391", "r1392", "r1394", "r1399", "r1433", "r1434", "r1435", "r1537", "r1539", "r1555" ] }, "fbio_DebtInstrumentNumberOfInterestOnlyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentNumberOfInterestOnlyPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of interest only period under the debt instrument.", "label": "Debt Instrument, Number Of Interest Only Period", "terseLabel": "Debt Instrument, number of interest only period" } } }, "auth_ref": [] }, "fbio_DebtInstrumentPercentageOfExitFees": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentPercentageOfExitFees", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents percentage of original principal amount to be paid as exit fees upon repayment of debt instrument.", "label": "Debt Instrument, Percentage of Exit Fees", "terseLabel": "Percentage of exit fee" } } }, "auth_ref": [] }, "fbio_DebtInstrumentPercentageOfPrincipalBalanceDue": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentPercentageOfPrincipalBalanceDue", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of principal balance due.", "label": "Debt Instrument, Percentage of Principal Balance Due", "terseLabel": "Percentage of principal balance due." } } }, "auth_ref": [] }, "fbio_DebtInstrumentPercentageOfThenOutstandingPrincipalBalanceDueOnSpecifiedDate": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentPercentageOfThenOutstandingPrincipalBalanceDueOnSpecifiedDate", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the then-outstanding principal balance of the loans due on specified date.", "label": "Debt Instrument, Percentage Of Then Outstanding Principal Balance Due On A Specified Date", "terseLabel": "Debt instrument, percentage of then outstanding principal balance due on a specified date" } } }, "auth_ref": [] }, "fbio_DebtInstrumentPeriodicPaymentPercentageOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentPeriodicPaymentPercentageOfPrincipalAmount", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the required periodic payments including both interest and principal payments on principal amount.", "label": "Debt Instrument, Periodic Payment, Percentage of Principal Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Repayments of principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r14" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r14", "r36", "r40", "r53", "r104", "r105", "r410", "r411", "r412", "r413", "r414", "r416", "r421", "r422", "r423", "r424", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r669", "r835", "r1076", "r1077", "r1078", "r1079", "r1080", "r1153", "r1391", "r1392", "r1394", "r1399", "r1537", "r1539" ] }, "fbio_DebtInstrumentThresholdAmountOfAggregateCommonEquityOrCashDistributionsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentThresholdAmountOfAggregateCommonEquityOrCashDistributionsToBeReceived", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold amount of aggregate common equity or cash distributions to be received as per the debt agreement.", "label": "Debt Instrument, Threshold Amount of Aggregate Common Equity or Cash Distributions to be Received", "terseLabel": "Debt instrument, threshold amount of aggregate common equity or cash distributions to be received" } } }, "auth_ref": [] }, "fbio_DebtInstrumentThresholdAmountOfOutstandingPrincipalForApplicabilityOfCovenants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentThresholdAmountOfOutstandingPrincipalForApplicabilityOfCovenants", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold amount of outstanding principal, above which the capital raise and minimum stake covenants and financial covenants shall be applicable.", "label": "Debt Instrument, Threshold Amount Of Outstanding Principal For Applicability Of Covenants", "terseLabel": "Outstanding principal balance" } } }, "auth_ref": [] }, "fbio_DebtInstrumentThresholdRevenueConsideredForNoPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtInstrumentThresholdRevenueConsideredForNoPeriodicPayment", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the threshold revenue for no periodic repayment of debt during the specified period.", "label": "Debt Instrument, Threshold Revenue Considered for No Periodic Payment", "terseLabel": "Percentage of revenue for no periodic repayment of debt" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less: Discount on notes payable", "verboseLabel": "Unamortized debt discount fees", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1450", "r1536", "r1537", "r1539" ] }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Debt instrument, unused borrowing capacity, amount", "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date." } } }, "auth_ref": [ "r62", "r396" ] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": [ "r837" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Debt, Policy [Policy Text Block]", "verboseLabel": "Issuance of Debt and Equity", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r9" ] }, "fbio_DebtPrepaymentPenalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DebtPrepaymentPenalties", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of prepayment of penalties.", "label": "Debt Prepayment Penalties" } } }, "auth_ref": [] }, "us-gaap_DeconsolidationGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeconsolidationGainOrLossAmount", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Deconsolidation, Gain (Loss), Amount", "negatedLabel": "Gain from deconsolidation of subsidiary", "terseLabel": "Gain from deconsolidation of subsidiary", "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer." } } }, "auth_ref": [ "r50", "r175" ] }, "fbio_DeconsolidationOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeconsolidationOfCommonStockWarrants", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to deconsolidation of common stock warrants.", "label": "Deconsolidation of Common Stock Warrants", "terseLabel": "Deconsolidation of common stock warrants" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredCompensationArrangementWithIndividualSharesIssued", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Shares Issued", "terseLabel": "Aggregate number of shares elected to deferred", "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement." } } }, "auth_ref": [ "r45" ] }, "fbio_DeferredDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredDividends", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred dividend payments at the end of the reporting period.", "label": "Deferred Dividends", "terseLabel": "Deferred dividends" } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1391", "r1397", "r1504", "r1505" ] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "verboseLabel": "Deferred" } } }, "auth_ref": [] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "terseLabel": "Unpaid debt offering cost", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r1427" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1391", "r1397", "r1504", "r1505" ] }, "fbio_DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent deferred tax assets amortization of in process research and development.", "label": "Deferred Tax Assets Amortization Of In Process Research And Development", "verboseLabel": "Amortization of in-process R&D" } } }, "auth_ref": [] }, "fbio_DeferredTaxAssetsAmortizationOfUpfrontFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxAssetsAmortizationOfUpfrontFees", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amortization of up-front fees in deferred tax asset.", "label": "Deferred Tax Assets Amortization Of Upfront Fees", "verboseLabel": "Amortization of license fees" } } }, "auth_ref": [] }, "fbio_DeferredTaxAssetsBusinessInterestExpenseDeductionLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxAssetsBusinessInterestExpenseDeductionLimit", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business interest expense deduction limit.", "label": "Deferred Tax Assets Business Interest Expense Deduction Limit", "terseLabel": "Business interest limitation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r576" ] }, "fbio_DeferredTaxAssetsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxAssetsLeaseLiability", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Deferred Tax Assets Lease Liability.", "label": "Deferred Tax Assets Lease Liability", "terseLabel": "Lease liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1498" ] }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]", "verboseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1502" ] }, "fbio_DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets reserve on sales return, discount and bad debt.", "label": "Deferred tax assets Reserve on Sales Return, Discount and Bad Debt", "terseLabel": "Reserve on Sales Return, Discount and Bad Debt" } } }, "auth_ref": [] }, "fbio_DeferredTaxAssetsSection174ResearchAndDevelopmentExpenditureCapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxAssetsSection174ResearchAndDevelopmentExpenditureCapitalization", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Section 174 R&D expenditure capitalization.", "label": "Deferred Tax Assets, Section 174 Research and Development Expenditure Capitalization", "terseLabel": "Section 174 R&D expenditure capitalization" } } }, "auth_ref": [] }, "fbio_DeferredTaxAssetsStartUpCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxAssetsStartUpCosts", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from start up costs.", "label": "Deferred Tax Assets, Start Up Costs", "verboseLabel": "Startup costs" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsStateTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsStateTaxes", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, State Taxes", "verboseLabel": "State taxes", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards", "verboseLabel": "Tax credits", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "verboseLabel": "Stock compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "verboseLabel": "Accruals and reserves", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsUnrealizedLossesOnTradingSecurities", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Asset, Debt Securities, Trading, Unrealized Loss", "verboseLabel": "Unrealized gain/loss on investments", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r577" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred tax liabilities, net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1498" ] }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs", "negatedLabel": "Debt issuance costs", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "verboseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Parent's Basis in Discontinued Operation", "negatedLabel": "Basis in subsidiary", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from the entity's basis in a discontinued operation." } } }, "auth_ref": [ "r46", "r1502" ] }, "fbio_DeferredTaxLiabilitiesRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Deferred Tax Liabilities Right of Use Asset.", "label": "Deferred Tax Liabilities Right of Use Asset", "negatedLabel": "Right of use asset" } } }, "auth_ref": [] }, "fbio_DeferredTaxLiabilitiesStateTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeferredTaxLiabilitiesStateTaxes", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from state taxes.", "label": "Deferred Tax Liabilities, State Taxes", "negatedLabel": "State taxes" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureEmployeeBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "verboseLabel": "Employer matching contribution", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r497" ] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureEmployeeBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "verboseLabel": "Employee contribution percentage", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r30", "r177", "r1047", "r1048", "r1050", "r1052" ] }, "fbio_DermatologyProductsSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DermatologyProductsSalesMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Dermatology Products Sales" } } }, "auth_ref": [] }, "fbio_DeskShareAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DeskShareAgreementsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Desk Share Agreements [Member]", "terseLabel": "Desk Share Agreements" } } }, "auth_ref": [] }, "fbio_DevelopmentAndRegulatoryPaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DevelopmentAndRegulatoryPaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of development and regulatory payments receivable under the agreement.", "label": "Development And Regulatory Payments Receivable", "terseLabel": "Development and regulatory milestone payments receivable", "verboseLabel": "Aggregate milestone payments receivable" } } }, "auth_ref": [] }, "fbio_DevelopmentMilestonePayableOutsideUSLicensingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DevelopmentMilestonePayableOutsideUSLicensingAgreements", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payable for development activities outside the US, under license agreement.", "label": "Development Milestone Payable, Outside U S, Licensing Agreements", "terseLabel": "Development milestone payable, outside US" } } }, "auth_ref": [] }, "fbio_DevelopmentMilestonePayableUSLicensingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DevelopmentMilestonePayableUSLicensingAgreements", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payable for development activities in US, under license agreement.", "label": "Development Milestone Payable, U S, Licensing Agreements", "terseLabel": "Development milestone payable, US" } } }, "auth_ref": [] }, "fbio_DirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DirectOfferingMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to direct offering.", "label": "Direct Offering [Member]", "terseLabel": "Direct offering" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "DirectorMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "auth_ref": [ "r1417", "r1589" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Revenues from Contracts and Significant Customers", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r482", "r483", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r482", "r483", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of total revenues", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1456" ] }, "fbio_DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreements" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of collaboration and stock purchase agreement text block.", "label": "Disclosure Of Collaboration And Stock Purchase Agreement [Text Block]", "verboseLabel": "Asset Purchase and Merger Agreements" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r144" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "fbio_DisposalGroupNotDiscontinuedOperationConsiderationExpectedPercentageOfAllFuturePaymentsAndRoyaltiesPayable": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DisposalGroupNotDiscontinuedOperationConsiderationExpectedPercentageOfAllFuturePaymentsAndRoyaltiesPayable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of expected receivables to all future payments and royalties payable in a disposal group not discontinued operation.", "label": "Disposal Group, Not Discontinued Operation, Consideration, Expected Percentage of All Future Payments And Royalties Payable", "terseLabel": "Percentage of expected receivables to all future payments and royalties payable" } } }, "auth_ref": [] }, "fbio_DisposalGroupNotDiscontinuedOperationConsiderationMilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DisposalGroupNotDiscontinuedOperationConsiderationMilestonePaymentReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments receivable for disposal group not a discontinued operation upon occurrence of event.", "label": "Disposal Group, Not Discontinued Operation, Consideration, Milestone Payment Receivable", "terseLabel": "Milestone payments receivable" } } }, "auth_ref": [] }, "fbio_DisposalGroupNotDiscontinuedOperationConsiderationUpfrontPaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DisposalGroupNotDiscontinuedOperationConsiderationUpfrontPaymentReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of upfront payment receivable for disposal group not a discontinued operation upon occurrence of event.", "label": "Disposal Group, Not Discontinued Operation, Consideration, Upfront Payment Receivable", "terseLabel": "Upfront payment receivable" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupNotDiscontinuedOperationsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Not Discontinued Operations [Member]", "terseLabel": "Disposal group, not discontinued operations", "documentation": "Disposal group that is not classified as discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r376", "r377", "r1096", "r1097" ] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsDeclaredTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Dividends Declared [Table Text Block]", "verboseLabel": "Schedule of PIK dividend or equity fee recorded", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "us-gaap_DividendsPaidinkind": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsPaidinkind", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails" ], "lang": { "en-us": { "role": { "label": "Dividends, Paid-in-kind", "verboseLabel": "Partner companies dividend", "documentation": "Amount of paid and unpaid paid-in-kind dividends (PIK) declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": [ "r3", "r106" ] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsPayableAmountPerShare", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Dividends Payable, Amount Per Share", "terseLabel": "Preferred Stock, dividend payable per share per annum", "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date." } } }, "auth_ref": [ "r22" ] }, "fbio_DividendsPayableDateOfRecordDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "DividendsPayableDateOfRecordDescription", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails" ], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend.", "label": "Dividends Payable Date Of Record Description", "verboseLabel": "PIK Dividend date" } } }, "auth_ref": [] }, "us-gaap_DividendsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails" ], "lang": { "en-us": { "role": { "label": "Dividends Receivable", "negatedLabel": "Dividends receivable", "documentation": "Carrying amount as of the balance sheet date of dividends declared but not received." } } }, "auth_ref": [ "r1327", "r1598" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1197", "r1198", "r1221" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1197", "r1198", "r1221", "r1264" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1242" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1195" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DomesticCountryMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "terseLabel": "Federal", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r556" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r1253" ] }, "fbio_EachIndicationAfterOccurrenceOfDevelopmentAndRegulatoryEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EachIndicationAfterOccurrenceOfDevelopmentAndRegulatoryEventsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to each indication after occurrence of development and regulatory events.", "label": "Each Indication After Occurrence of Development And Regulatory Events [Member]", "terseLabel": "Each indication after occurrence of development and regulatory events" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Common Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share attributable to common stockholders - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r140", "r170", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r218", "r221", "r225", "r226", "r227", "r232", "r441", "r535", "r596", "r652", "r682", "r683", "r830", "r862", "r1056" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share attributable to common stockholders - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r140", "r170", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r221", "r225", "r226", "r227", "r232", "r441", "r535", "r596", "r652", "r682", "r683", "r830", "r862", "r1056" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r24", "r25", "r229" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss per Common Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r217", "r228", "r230", "r231" ] }, "fbio_EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "documentation": "The effect of series A preferred dividends on net loss per share calculation.", "label": "Effect of Series A Preferred Dividends On Net Loss Per Share Calculation", "terseLabel": "Effect of Series A preferred dividends on net loss per share calculation" } } }, "auth_ref": [] }, "fbio_EffectOfSubsidiaryDeemedDividendsOnNetIncomeLossPerShareCalculation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EffectOfSubsidiaryDeemedDividendsOnNetIncomeLossPerShareCalculation", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "documentation": "The effect of subsidiaries deemed dividends on net income (loss) per share calculation.", "label": "Effect of Subsidiary Deemed Dividends On Net Income (Loss) Per Share Calculation", "terseLabel": "Effect of subsidiaries deemed dividends" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate", "verboseLabel": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r556", "r1102" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. federal statutory tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r188", "r193", "r556", "r586", "r1102" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r561", "r1102", "r1391", "r1398", "r1493" ] }, "fbio_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the state rates.", "label": "Effective Income Tax Rate Reconciliation, Change in State Rate, Percent", "terseLabel": "Change in state rate" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent", "terseLabel": "Sale of IP", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory." } } }, "auth_ref": [ "r1391", "r1398", "r1493", "r1494" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent", "terseLabel": "Sale of subsidiaries", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation." } } }, "auth_ref": [ "r1391", "r1398", "r1493", "r1494" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent", "negatedLabel": "Change in subsidiary basis", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes." } } }, "auth_ref": [ "r1391", "r1398", "r1493", "r1494" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Non-deductible items", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r562", "r564", "r1391", "r1398", "r1493" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r1102", "r1391", "r1398", "r1493", "r1495" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "terseLabel": "Share-based compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r1102", "r1391", "r1398", "r1493", "r1495" ] }, "fbio_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transaction costs.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Amount", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "fbio_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercentage", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transaction costs.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Percentage", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1102", "r1391", "r1398", "r1493", "r1494" ] }, "fbio_EffectiveIncomeTaxRateReconciliationSection162mCompensationDisallowance": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationSection162mCompensationDisallowance", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from the section 162(m) compensation disallowance.", "label": "Effective Income Tax Rate Reconciliation, Section162m Compensation Disallowance", "terseLabel": "Section 162(m) compensation disallowance" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local income taxes, net of federal income tax effect1", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r559", "r1102", "r1391", "r1398", "r1493" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]", "documentation": "Indicates name of state or local jurisdiction that makes up greater than 50 percent of effect of state and local income tax." } } }, "auth_ref": [ "r565", "r1102" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent", "terseLabel": "Changes in unrecognized tax benefits", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r563", "r1102", "r1391", "r1398", "r1493" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "negatedLabel": "Tax credits", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r560", "r564", "r1391", "r1398", "r1493" ] }, "fbio_EmployeeAndNonemployeeAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EmployeeAndNonemployeeAwardsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to employee and non-employee awards.", "label": "Employee And Nonemployee Awards [Member]", "terseLabel": "Employee and non-employee awards" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r533" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Share-based compensation, period for recognition of expense", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r533" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized compensation expense for awards other than options", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1488" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "verboseLabel": "Stock options, unrecognized compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1488" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Options to purchase Common Stock", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "fbio_EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the employee stock purchase plan offering fair value reckoning percentage.", "label": "Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage", "terseLabel": "Predetermined fair value percentage during offering period" } } }, "auth_ref": [] }, "fbio_EmployeesAndNonEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EmployeesAndNonEmployeesMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Employees And Non Employees [Member]", "label": "Employees And Non Employees [Member]", "terseLabel": "Employees And Non Employees" } } }, "auth_ref": [] }, "fbio_EmrosiLicenseCollaborationAndAssignmentAgreementForDevelopmentAndCommercializationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EmrosiLicenseCollaborationAndAssignmentAgreementForDevelopmentAndCommercializationMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Emrosi, license, collaboration and assignment agreement for development and commercialization", "label": "Emrosi, License, Collaboration And Assignment Agreement For Development And Commercialization [Member]", "verboseLabel": "Emrosi Agreement" } } }, "auth_ref": [] }, "fbio_EmrosiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EmrosiMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Emrosi", "label": "Emrosi [Member]", "terseLabel": "Emrosi" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1194" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1194" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1194" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1304" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1194" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1194" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1194" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1194" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1305" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r1247" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1300" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1300" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1300" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r137", "r139", "r140", "r166", "r167", "r168", "r200", "r201", "r202", "r204", "r211", "r213", "r215", "r234", "r327", "r328", "r373", "r440", "r461", "r535", "r584", "r585", "r593", "r594", "r595", "r597", "r651", "r652", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r714", "r715", "r716", "r717", "r718", "r719", "r724", "r726", "r742", "r859", "r889", "r890", "r891", "r915", "r984" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r323", "r324", "r325", "r592", "r710", "r1309", "r1310", "r1311", "r1506", "r1507", "r1508", "r1509" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments", "terseLabel": "Change in fair value of equity method investment accounted for at fair value within other income", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r233", "r258", "r277", "r322", "r1323", "r1425" ] }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityMethodInvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments, Fair Value Disclosure", "terseLabel": "Fair value option and estimated the fair value", "documentation": "Fair value portion of investments accounted under the equity method." } } }, "auth_ref": [ "r708", "r1037", "r1152", "r1324", "r1526", "r1527", "r1531" ] }, "fbio_EquityOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EquityOfferingMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the entity's sale of stock through equity offering.", "label": "Equity Offering [Member]", "terseLabel": "February 2025 Equity Offering" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity investments, at fair value", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": [ "r704" ] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI", "terseLabel": "Estimated fair value", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r155", "r685", "r704", "r705", "r706", "r707", "r840", "r841", "r1141", "r1179", "r1181", "r1528", "r1529", "r1530" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Change in fair value of investment", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r864", "r1424" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1257" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1214", "r1225", "r1235", "r1268" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r1211", "r1222", "r1232", "r1265" ] }, "fbio_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Eunice Kennedy Shriver National Institute of Child Health and Human Development.", "label": "Eunice Kennedy Shriver National Institute of Child Health and Human Development [Member]", "terseLabel": "Eunice Kennedy Shriver National Institute of Child Health and Human Development" } } }, "auth_ref": [] }, "fbio_Excesspershareexercisepriceofwarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "Excesspershareexercisepriceofwarrants", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Excess amount per share or per unit of warrants or rights outstanding.", "label": "Excess Per Share Exercise Price Of Warrants", "terseLabel": "Excess over per share exercise price for warrants" } } }, "auth_ref": [] }, "fbio_ExchangeOfPartnerCompanyConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ExchangeOfPartnerCompanyConvertiblePreferredShares", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange of partner company convertible preferred shares, classified as non-cash activities.", "label": "Exchange of Partner Company Convertible Preferred Shares", "terseLabel": "Exchange of partner company convertible preferred shares for common shares" } } }, "auth_ref": [] }, "fbio_ExecutiveAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ExecutiveAwardsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Executive Awards [Member]", "terseLabel": "Executive awards" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1263" ] }, "srt_ExecutiveVicePresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ExecutiveVicePresidentMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Executive Vice President [Member]", "terseLabel": "Executive Vice President (Mr. Weiss)" } } }, "auth_ref": [ "r1417" ] }, "fbio_ExecutivesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ExecutivesAndDirectorsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Executives and Directors [Member]", "label": "Executives and Directors [Member]", "terseLabel": "Executives and Directors" } } }, "auth_ref": [] }, "fbio_ExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ExerciseOfCommonStockWarrants", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise of common stock warrants.", "label": "Exercise Of Common Stock Warrants", "terseLabel": "Exercise of common stock warrants" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "terseLabel": "Gain (loss) on common stock warrant liabilities", "verboseLabel": "Change in fair value of common stock warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r6" ] }, "us-gaap_FairValueAdjustmentToInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAdjustmentToInventoryMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment to Inventory [Member]", "terseLabel": "Fair Value Adjustment to Inventory", "documentation": "Nonrecurring fair value adjustment for inventory at acquisition date attributable to business combination included in reported pro forma earnings." } } }, "auth_ref": [ "r1103", "r1107", "r1512", "r1513" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r685", "r686", "r696", "r1141" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r685", "r686", "r696", "r1141" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r687", "r688", "r689", "r1103", "r1105", "r1145" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r687", "r688", "r689", "r1103", "r1105", "r1145" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of the Weighted average Significant Unobservable Inputs", "verboseLabel": "Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r687", "r688", "r1145" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r423", "r487", "r488", "r489", "r490", "r491", "r492", "r494", "r495", "r684", "r686", "r687", "r688", "r689", "r695", "r696", "r698", "r705", "r758", "r759", "r760", "r1037", "r1077", "r1078", "r1091", "r1092", "r1093", "r1094", "r1095", "r1141", "r1145", "r1152" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r687", "r691", "r693", "r694", "r695", "r698", "r699", "r700", "r701", "r702", "r829", "r1141", "r1146" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r423", "r487", "r488", "r489", "r490", "r491", "r492", "r494", "r495", "r686", "r687", "r688", "r689", "r696", "r705", "r760", "r1037", "r1077", "r1078", "r1091", "r1092", "r1093", "r1094", "r1095", "r1141", "r1145", "r1152" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "verboseLabel": "Fair Value Measurement", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r423", "r487", "r488", "r489", "r490", "r491", "r492", "r494", "r495", "r684", "r686", "r687", "r688", "r689", "r695", "r696", "r698", "r705", "r758", "r759", "r760", "r1037", "r1077", "r1078", "r1091", "r1092", "r1093", "r1094", "r1095", "r1141", "r1145", "r1152" ] }, "fbio_FairValueOfAssetsInRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FairValueOfAssetsInRepurchaseTransaction", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value of assets under the repurchase transaction the fair value of assets under the repurchase transaction.", "label": "Fair Value Of Assets In Repurchase Transaction", "terseLabel": "Repurchased assets on relative fair value basis" } } }, "auth_ref": [] }, "fbio_FairValueOfAssetsReceivedByPartnerCompanyInRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FairValueOfAssetsReceivedByPartnerCompanyInRepurchaseTransaction", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange fair value of assets received by partner company in repurchase transaction.", "label": "Fair value of assets received by partner company in repurchase transaction", "terseLabel": "Fair value of assets received by partner company in repurchase transaction" } } }, "auth_ref": [] }, "fbio_FairValueOfSuppliesReceivedByPartnerCompanyExpensedToResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FairValueOfSuppliesReceivedByPartnerCompanyExpensedToResearchAndDevelopment", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange fair value of supplies received by partner company expensed to research and development", "label": "Fair value of supplies received by partner company expensed to research and development", "terseLabel": "Fair value of supplies received by partner company expensed to research and development" } } }, "auth_ref": [] }, "fbio_FairValueOfWarrantsAndRightsOutstandingBasedOnValuationInputs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FairValueOfWarrantsAndRightsOutstandingBasedOnValuationInputs", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of outstanding derivative securities based on valuation technique that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Fair Value of Warrants and Rights Outstanding Based On Valuation Inputs", "terseLabel": "Yield value" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r330", "r331", "r335", "r336", "r337", "r338", "r339", "r340", "r434", "r458", "r669", "r680", "r703", "r709", "r712", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r839", "r860", "r1073", "r1141", "r1143", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1156", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1420", "r1421", "r1422", "r1423", "r1525", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534" ] }, "fbio_FinancialMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FinancialMilestonesMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Financial Milestones [Member]", "label": "Financial Milestones [Member]", "terseLabel": "Financial Milestones" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible assets, estimated useful lives", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r152", "r344", "r364", "r1040" ] }, "fbio_FiniteLivedIntangibleAssetsAccumulatedImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for finite lived intangible assets.", "label": "Finite Lived Intangible Assets, Accumulated Impairment", "negatedLabel": "Accumulated Impairment loss" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1431", "r1599" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r1035", "r1040" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2030", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r1035", "r1040" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2029", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r1035", "r1040" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r1035", "r1040" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r366", "r1035", "r1040" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r356", "r358", "r359", "r360", "r363", "r364", "r368", "r369", "r793", "r794", "r896", "r1035", "r1040", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Intangible assets - product licenses", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r344", "r364", "r794", "r1040" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r356", "r364", "r368", "r369", "r371", "r793", "r1035", "r1040", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r356", "r358", "r359", "r360", "r363", "r364", "r368", "r369", "r896", "r1035", "r1040", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net intangible assets", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r793", "r1430" ] }, "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Finite Lived Intangible Assets Net, Excluding assets that has not been placed in service.", "label": "Finite Lived Intangible Assets Net, Excluding assets that has not been placed in service", "totalLabel": "Sub-total" } } }, "auth_ref": [] }, "fbio_FirstSpecifiedPeriodOrConditionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FirstSpecifiedPeriodOrConditionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to first specified period or condition.", "label": "First Specified Period Or Condition [Member]" } } }, "auth_ref": [] }, "fbio_FoamFranchiseProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FoamFranchiseProductsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to foam franchise products.", "label": "Foam Franchise Products [Member]", "terseLabel": "Foam franchise products (Amzeeq & Zilxi)" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1272" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1272" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1272" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1272" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1272" ] }, "fbio_FortressBiotechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FortressBiotechIncMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Fortress Biotech Inc.", "label": "Fortress Biotech Inc [Member]", "terseLabel": "Fortress" } } }, "auth_ref": [] }, "fbio_FoundersAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "FoundersAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Founders Agreement [Member]", "terseLabel": "Founder agreement with Mustang", "verboseLabel": "Founder agreement" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r1252" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "fbio_GainFromReversalOfFinancingRelatedObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "GainFromReversalOfFinancingRelatedObligation", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) from reversal of financial obligation.", "label": "Gain from Reversal of Financing Related Obligation", "terseLabel": "Repurchase option liability" } } }, "auth_ref": [] }, "fbio_GainLossOnCommonStockWarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "GainLossOnCommonStockWarrantLiabilities", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on common stock warrant liabilities.", "label": "Gain/Loss on common stock warrant liabilities", "terseLabel": "Gain (loss) on common stock warrant liabilities", "verboseLabel": "Loss on common stock warrant liabilities" } } }, "auth_ref": [] }, "fbio_GainLossOnRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "GainLossOnRecovery", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on recovery.", "label": "Gain (Loss) on Recovery", "negatedLabel": "Loss recovery" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r6" ] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "terseLabel": "Gain on sale of asset", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } } }, "auth_ref": [ "r1387" ] }, "fbio_GainLossOnSettlementOfPartnerCompanyInstallmentPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "GainLossOnSettlementOfPartnerCompanyInstallmentPayments", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "The gain (loss) accounted for the settlement of license installment payment, for the difference between the carrying value of the license installment payments and the settlement amount.", "label": "Gain Loss on Settlement of Partner Company Installment Payments" } } }, "auth_ref": [] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Gain on termination of partner company lease", "terseLabel": "Net gain", "verboseLabel": "Net gain on lease termination", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": [ "r727" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "verboseLabel": "Gain (loss) on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r6", "r33", "r34" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "verboseLabel": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r82" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_GrossInvestmentIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GrossInvestmentIncomeOperating", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Gross Investment Income, Operating", "negatedLabel": "Interest expense (income), interest", "documentation": "Amount, before investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": [ "r861", "r1190", "r1594" ] }, "us-gaap_GuaranteeObligationsMaximumExposure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GuaranteeObligationsMaximumExposure", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "terseLabel": "Aggregate amount", "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions." } } }, "auth_ref": [ "r395" ] }, "fbio_HelocyteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "HelocyteMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Helocyte [Member]", "terseLabel": "Helocyte" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1197", "r1198", "r1221" ] }, "fbio_IdbNotePayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IdbNotePayableMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "IDB Note Payable [Member]", "label": "IDB Note Payable [Member]", "terseLabel": "IDB Note Payable" } } }, "auth_ref": [] }, "fbio_IfMilestoneAchievedOnOrAfterDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingMoreFrequentThanEveryThreeWeeksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IfMilestoneAchievedOnOrAfterDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingMoreFrequentThanEveryThreeWeeksMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a scenario when milestone is achieved on or after the date that is 12 months prior to milestone deadline date and approval provides for a dosing schedule that is more frequent than once every three weeks.", "label": "If Milestone Achieved On Or After Date That Is 12 Months Prior To Deadline Date And Approvals For Dosing More Frequent Than Every Three Weeks [Member]", "terseLabel": "If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule more frequent than once every three weeks" } } }, "auth_ref": [] }, "fbio_IfMilestoneAchievedOnOrAfterDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingOnceEveryThreeWeeksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IfMilestoneAchievedOnOrAfterDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingOnceEveryThreeWeeksMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a scenario when milestone is achieved on or after the date that is 12 months prior to milestone deadline date and approval provides for a dosing schedule of once every three weeks.", "label": "If Milestone Achieved On Or After Date That Is 12 Months Prior To Deadline Date And Approvals For Dosing Once Every Three Weeks [Member]", "terseLabel": "If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule once every three weeks" } } }, "auth_ref": [] }, "fbio_IfMilestoneAchievedOnOrBeforeDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingMoreFrequentThanEveryThreeWeeksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IfMilestoneAchievedOnOrBeforeDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingMoreFrequentThanEveryThreeWeeksMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a scenario when milestone is achieved on or prior to the date that is 12 months prior to milestone deadline date and approval provides for a dosing schedule that is more frequent than once every three weeks.", "label": "If Milestone Achieved On Or Before Date That Is 12 Months Prior To Deadline Date And Approvals For Dosing More Frequent Than Every Three Weeks [Member]", "terseLabel": "If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of more frequent than once every three weeks" } } }, "auth_ref": [] }, "fbio_IfMilestoneAchievedOnOrBeforeDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingOnceEveryThreeWeeksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IfMilestoneAchievedOnOrBeforeDateThatIs12MonthsPriorToDeadlineDateAndApprovalsForDosingOnceEveryThreeWeeksMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a scenario when milestone is achieved on or prior to the date that is 12 months prior to milestone deadline date and approval provides for a dosing schedule of once every three weeks.", "label": "If Milestone Achieved On Or Before Date That Is 12 Months Prior To Deadline Date And Approvals For Dosing Once Every Three Weeks [Member]", "terseLabel": "If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of once every three weeks" } } }, "auth_ref": [] }, "fbio_IfOutstandingPrincipalBalanceIsBetween10MillionAnd25MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IfOutstandingPrincipalBalanceIsBetween10MillionAnd25MillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the scenario when the outstanding principal balance is between 10 million and 25 million.", "label": "If the Outstanding Principal Balance is Between 10 Million and 25 Million [Member]", "terseLabel": "Scenario when the outstanding principal balance is between 10 million and 25 million" } } }, "auth_ref": [] }, "fbio_IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the scenario when the outstanding principal balance is less than or equal to 10 million.", "label": "If the Outstanding Principal Balance is Less Than or Equal to 10 Million [Member]", "terseLabel": "Scenario when the outstanding principal balance is less than or equal to 10 million" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLeasehold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfLeasehold", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Leasehold", "terseLabel": "Impairment loss allocated to leasehold improvements", "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced." } } }, "auth_ref": [ "r6", "r29" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Asset impairment loss", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r6", "r29", "r100", "r174", "r1048", "r1142" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "verboseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r101" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r77", "r117", "r121", "r831", "r833", "r855", "r1049", "r1051", "r1053", "r1060", "r1066", "r1407", "r1413", "r1414", "r1415", "r1416" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r376", "r377", "r1096", "r1097" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r374", "r383", "r384", "r665", "r666", "r667", "r668", "r690", "r692", "r697", "r711", "r712", "r713", "r886", "r888", "r969", "r1035", "r1037", "r1103", "r1104", "r1139", "r1140", "r1144", "r1152", "r1510", "r1513", "r1559" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r383", "r384", "r665", "r666", "r667", "r668", "r690", "r692", "r697", "r711", "r712", "r713", "r886", "r888", "r969", "r1035", "r1037", "r1103", "r1104", "r1139", "r1140", "r1144", "r1152", "r1510", "r1513", "r1559" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r184", "r556", "r557", "r569", "r581", "r1102", "r1501" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r184", "r556", "r557", "r569", "r581", "r1102", "r1501" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r569", "r1501" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r569", "r1501" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income taxes" } } }, "auth_ref": [] }, "fbio_IncomeTaxDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IncomeTaxDisclosureLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Disclosure [Line Items]", "terseLabel": "Income taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r188", "r193", "r551", "r556", "r565", "r566", "r567", "r573", "r579", "r587", "r589", "r590", "r591", "r838", "r895", "r909", "r1102" ] }, "fbio_IncomeTaxEffectChangeInLawAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IncomeTaxEffectChangeInLawAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by income tax effect of change in law.", "label": "Income Tax Effect, Change in Law [Axis]" } } }, "auth_ref": [] }, "fbio_IncomeTaxEffectChangeInLawDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IncomeTaxEffectChangeInLawDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Income tax effect of change in law.", "label": "Income Tax Effect, Change in Law [Domain]" } } }, "auth_ref": [] }, "fbio_IncomeTaxEffectUsPublicLaw11921Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IncomeTaxEffectUsPublicLaw11921Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Income tax effect of United States of America (US) Public Law 119-21 (House of Representatives (H.R.) 1 of 119th Congress).", "label": "Income Tax Effect, US Public Law 119-21 [Member]", "terseLabel": "Income Tax Effect, US Public Law 119-21" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExaminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExaminationDescription", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Examination, Description", "terseLabel": "Income tax examination", "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings." } } }, "auth_ref": [ "r1497" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 }, "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense", "totalLabel": "Total", "verboseLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r124", "r132", "r188", "r214", "r215", "r233", "r255", "r277", "r555", "r556", "r588", "r866", "r1049", "r1051", "r1053", "r1102" ] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]", "terseLabel": "Income Taxes", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r184", "r581" ] }, "us-gaap_IncomeTaxPaidByIndividualJurisdictionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPaidByIndividualJurisdictionTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Paid, by Individual Jurisdiction [Table]", "documentation": "Disclosure of information about income tax paid by jurisdiction." } } }, "auth_ref": [ "r184", "r581" ] }, "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPaidFederalAfterRefundReceived", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails": { "parentTag": "us-gaap_IncomeTaxesPaidNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Paid, Federal, after Refund Received", "terseLabel": "Federal", "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income." } } }, "auth_ref": [ "r184", "r580" ] }, "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails": { "parentTag": "us-gaap_IncomeTaxesPaidNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Paid, State and Local, after Refund Received", "terseLabel": "State", "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income." } } }, "auth_ref": [ "r184", "r580" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r165", "r553", "r554", "r573", "r574", "r578", "r583", "r903" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r561", "r1102", "r1493" ] }, "us-gaap_IncomeTaxReconciliationDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationDispositionOfAssets", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount", "terseLabel": "Sale of IP", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory." } } }, "auth_ref": [ "r1493", "r1494" ] }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationDispositionOfBusiness", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount", "terseLabel": "Sale of subsidiaries", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation." } } }, "auth_ref": [ "r1493", "r1494" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "U.S. federal statutory tax rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r556", "r1102" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "terseLabel": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r1102", "r1493", "r1495" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "terseLabel": "Share-based compensation", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1102", "r1493", "r1495" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1102", "r1493", "r1494" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State and local income taxes, net of federal income tax effect", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r559", "r1102", "r1493" ] }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "terseLabel": "Changes in unrecognized tax benefits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r563", "r1102", "r1493" ] }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationTaxCredits", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Tax credits", "verboseLabel": "Income tax credits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r560", "r564", "r1493" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "totalLabel": "Income Taxes Paid, Net, Total", "verboseLabel": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r21", "r184", "r580", "r581" ] }, "us-gaap_IncreaseDecreaseDueFromOtherRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseDueFromOtherRelatedParties", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) Due from Other Related Parties", "negatedLabel": "Other receivables - related party", "documentation": "Amount of increase (decrease) in receivables due from related parties classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories", "verboseLabel": "Finished goods inventory, fair value step-up", "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "fbio_IncreaseDecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IncreaseDecreaseInLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase decrease in lease liabilities.", "label": "Increase Decrease In Lease Liabilities", "verboseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 23.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 27.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r356", "r367", "r371", "r1040", "r1108", "r1109", "r1110", "r1119", "r1120", "r1134" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1263", "r1272", "r1276", "r1284" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r1282" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r1199", "r1288" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r1199", "r1288" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r1199", "r1288" ] }, "fbio_InstallmentOnDecember12024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "InstallmentOnDecember12024Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to installment payable on December 1, 2024.", "label": "Installment on December 1, 2024 [Member]", "terseLabel": "Installment on December 1, 2024" } } }, "auth_ref": [] }, "fbio_InstallmentOnJanuary152025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "InstallmentOnJanuary152025Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to installment payable on December 1, 2024.", "label": "Installment on January 15, 2025 [Member]", "terseLabel": "Installment on January 15, 2025" } } }, "auth_ref": [] }, "fbio_InstallmentUponExecutionOfSettlementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "InstallmentUponExecutionOfSettlementAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to installment payable upon execution of settlement agreement.", "label": "Installment Upon Execution of Settlement Agreement [Member]", "terseLabel": "Installment Upon Execution of Settlement Agreement" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "Intangible Assets, net", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r355", "r370", "r372", "r1034", "r1035" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r789", "r790", "r791", "r793", "r1054", "r1428" ] }, "fbio_IntangibleAssetsNotYetPlacedInService": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IntangibleAssetsNotYetPlacedInService", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Intangible assets not yet placed in service", "label": "Intangible assets not yet placed in service", "terseLabel": "Asset not yet placed in service" } } }, "auth_ref": [] }, "us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestAndDividendIncomeSecuritiesHeldToMaturity", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Income, Debt Securities, Held-to-Maturity", "documentation": "Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Operating and Nonoperating", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r233", "r247", "r251", "r257", "r277", "r721", "r1066", "r1067", "r1592" ] }, "fbio_InterestExpenseAndFinanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "InterestExpenseAndFinanceFees", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense and amount of debt issuance costs.", "label": "Interest Expense And Finance Fees", "negatedLabel": "Interest expense and financing fee" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "totalLabel": "Interest expense, Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r84", "r429", "r439", "r1079", "r1080", "r1592" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "verboseLabel": "Interest expense, interest", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r84", "r430", "r1079", "r1080" ] }, "fbio_InterestExpenseTotalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "InterestExpenseTotalNet", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Net Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense, Total, Net", "totalLabel": "Interest Expense (Income), Total" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r179", "r182", "r183" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r120", "r233", "r249", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r1066" ] }, "fbio_InvagenPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "InvagenPharmaceuticalsIncMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to InvaGen Pharmaceuticals Inc.", "label": "InvaGen [Member]", "terseLabel": "InvaGen" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventory" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventory", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r341" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "verboseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1328" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Gross", "totalLabel": "Inventory at cost", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1330" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r161", "r1042", "r1155" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r126", "r148", "r160", "r341", "r342", "r343", "r788", "r1055" ] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials and Supplies, Gross", "verboseLabel": "Raw materials", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r1330" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory reserve", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r96", "r1330" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1329" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "verboseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r233", "r250", "r277", "r1066", "r1342" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment in Equity Securities", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r863", "r899", "r900", "r901", "r902", "r993", "r994" ] }, "fbio_IssuanceOfCommonStockForAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IssuanceOfCommonStockForAtMarketOffering", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period for cash at the market cost.", "label": "Issuance of Common Stock for At the Market Offering", "terseLabel": "Issuance of common stock for at-the-market offering, net" } } }, "auth_ref": [] }, "fbio_IssuanceOfCommonStockForAtMarketOfferingInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IssuanceOfCommonStockForAtMarketOfferingInShares", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "It represents the stock issued during period shares issued for cash at market cost.", "label": "Issuance of Common Stock for At the Market Offering in shares", "terseLabel": "Issuance of common stock for at-the-market offering, net (in shares)" } } }, "auth_ref": [] }, "fbio_IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock under partner company's Employee stock purchase program.", "label": "Issuance of common stock under partner company's Employee stock purchase program", "terseLabel": "Issuance of common stock under partner company's ESPP" } } }, "auth_ref": [] }, "fbio_JM17LicenseAgreementForIntellectualPropertyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "JM17LicenseAgreementForIntellectualPropertyRightsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to JM17, license agreement for intellectual property rights", "label": "J M 17, License Agreement For Intellectual Property Rights [Member]", "terseLabel": "JM17", "verboseLabel": "AnnJi License Agreement" } } }, "auth_ref": [] }, "fbio_JM17TerminationAndTransferAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "JM17TerminationAndTransferAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to JM17, termination and transfer agreement", "label": "J M 17, Termination And Transfer Agreement [Member]", "terseLabel": "AnnJi license termination and program transfer", "verboseLabel": "Termination and Transfer Agreement" } } }, "auth_ref": [] }, "fbio_January2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "January2023WarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to January 2023 Warrants.", "label": "January 2023 Warrants [Member]", "terseLabel": "January 2023 Warrants" } } }, "auth_ref": [] }, "fbio_January2025WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "January2025WarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the warrants issued in January 2025", "label": "January 2025 Warrants [Member]", "terseLabel": "2025 Warrant" } } }, "auth_ref": [] }, "fbio_JourneyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "JourneyMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsScheduleOfNonControllingInterestsInConsolidatedEntitiesDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Journey", "terseLabel": "Journey" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total lease expense", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r732", "r1154" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1543" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseExpirationDate1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lease Expiration Date", "terseLabel": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "fbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LeaseLiabilitiesArisingFromObtainingRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amounts paid for lease liabilities arising from obtaining right-to-use assets.", "label": "Lease Liabilities arising from obtaining right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseholdsAndLeaseholdImprovementsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement." } } }, "auth_ref": [ "r99" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "fbio_LegalExpenseReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LegalExpenseReimbursement", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of legal expense reimbursed during the period.", "label": "Legal Expense Reimbursement", "terseLabel": "Legal expense reimbursed" } } }, "auth_ref": [] }, "fbio_LesseeLeasePortfolioAndOtherSupplementalLeaseInformation": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LesseeLeasePortfolioAndOtherSupplementalLeaseInformation", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "documentation": "Lessee Lease Portfolio and Other Supplemental Lease Information", "label": "Lessee Lease Portfolio and Other Supplemental Lease Information", "terseLabel": "Summary of Quantitative Information about Operating Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r731" ] }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseDescriptionAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Lessee, Operating Lease, Description" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1544" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total operating lease liabilities", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r740", "r1392", "r1399", "r1555" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year ended December 31, 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r740", "r1392", "r1399", "r1555" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "Year ended December 31, 2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r740", "r1392", "r1399", "r1555" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "Year ended December 31, 2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r740", "r1392", "r1399", "r1555" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "Year ended December 31, 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r740", "r1392", "r1399", "r1555" ] }, "fbio_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: present value discount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r740" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "verboseLabel": "Operating lease term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1542" ] }, "fbio_LesseeOperatingSubleaseBaseRentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LesseeOperatingSubleaseBaseRentReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of base rent receivable from operating sublease .", "label": "Lessee, Operating Sublease, Base Rent Receivable", "terseLabel": "Base rent receivable" } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LetterOfCreditMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "terseLabel": "LOC Fees", "verboseLabel": "Letter of Credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [ "r1176", "r1178" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r57", "r58", "r59", "r63", "r64", "r65", "r66", "r188", "r191", "r192", "r326", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r658", "r663", "r664", "r710", "r939", "r1059", "r1081", "r1192", "r1445", "r1547", "r1548" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r73", "r116", "r850", "r1155", "r1175", "r1177", "r1391", "r1396", "r1426", "r1535" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r59", "r147", "r188", "r191", "r192", "r326", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r658", "r663", "r664", "r710", "r1155", "r1445", "r1547", "r1548" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "fbio_LicenseAgreementConsiderationPaidInEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LicenseAgreementConsiderationPaidInEquity", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of consideration paid in the form of equity under license agreement", "label": "License Agreement, Consideration Paid In Equity", "terseLabel": "Consideration paid" } } }, "auth_ref": [] }, "fbio_LicenseAgreementNumberOfProductsAgreedToAcquire": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LicenseAgreementNumberOfProductsAgreedToAcquire", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of products agreed to be acquired under license agreement.", "label": "License Agreement, Number Of Products Agreed To Acquire", "terseLabel": "Number of products agreed to be acquired under license agreement" } } }, "auth_ref": [] }, "fbio_LicenseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LicenseAgreementsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to license agreements.", "label": "License Agreements [Member]", "terseLabel": "Various license agreements" } } }, "auth_ref": [] }, "fbio_LicenseAgreementsSaleBasedMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LicenseAgreementsSaleBasedMilestonePayments", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of sale based milestone payments payable in license agreements.", "label": "License Agreements, Sale Based Milestone Payments", "terseLabel": "Sales-based milestone payments paid and payable to date" } } }, "auth_ref": [] }, "fbio_LicenseAgreementsUpfrontAndMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LicenseAgreementsUpfrontAndMilestonePayments", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of upfront and milestone payments on license agreements.", "label": "License Agreements, Upfront and Milestone Payments", "terseLabel": "Aggregate upfront and milestone payments paid and payable to date" } } }, "auth_ref": [] }, "fbio_LicensesAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LicensesAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "na.", "label": "License Agreements" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r56", "r62" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "verboseLabel": "Remaining borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r56", "r62", "r397" ] }, "fbio_LoansDueOnDecember302027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LoansDueOnDecember302027Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to scenario in which loan portion of loan is due on December 30, 2027.", "label": "Loans Due On December 30, 2027 [Member]", "terseLabel": "Loan due on December 30, 2027" } } }, "auth_ref": [] }, "fbio_LoansDueOnMarch312028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LoansDueOnMarch312028Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to scenario in which loan portion of loan is due on March 31, 2028.", "label": "Loans Due On March 31, 2028 [Member]", "terseLabel": "Loan due on March 31, 2028" } } }, "auth_ref": [] }, "fbio_LoansDueOnSeptember302027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LoansDueOnSeptember302027Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to scenario in which loan portion of loan is due on September 30, 2027 .", "label": "Loans Due On September 30, 2027 [Member]", "terseLabel": "Loan due on September 30, 2027" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Total notes payable, long term, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r14", "r113", "r189", "r199", "r422", "r437", "r835", "r1077", "r1078", "r1153", "r1556" ] }, "fbio_LongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LongTermIncentivePlanMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term Incentive Plan [Member]", "label": "Long term Incentive Plan [Member]", "terseLabel": "LTIP" } } }, "auth_ref": [] }, "fbio_LongTermIncentiveProgramPercentageOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LongTermIncentiveProgramPercentageOfOutstandingShares", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term incentive program Percentage of outstanding shares", "label": "Long term incentive program Percentage of outstanding shares", "terseLabel": "LTIP, Percentage of outstanding shares" } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Noncurrent", "verboseLabel": "Notes payable, long-term, net", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r14" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r242", "r389", "r390", "r391", "r394", "r547", "r1075", "r1438", "r1439" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingenciesTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r242", "r389", "r390", "r391", "r394", "r547", "r1075", "r1438", "r1439" ] }, "us-gaap_LossContingencyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Receivable", "terseLabel": "Loss contingency, receivable", "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable." } } }, "auth_ref": [ "r1442" ] }, "fbio_LossContingencyReceivableOnRegulatoryApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LossContingencyReceivableOnRegulatoryApproval", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of receivable related to a loss contingency accrual on approval from regulatory authority.", "label": "Loss Contingency Receivable on Regulatory Approval", "terseLabel": "Amount of receivable related to a loss contingency" } } }, "auth_ref": [] }, "fbio_LossRecoveryOfCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "LossRecoveryOfCosts", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of loss recovery of costs during the period.", "label": "Loss Recovery of Costs", "negatedLabel": "Loss recovery" } } }, "auth_ref": [] }, "fbio_MaintainsVotingControlMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MaintainsVotingControlMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Maintains Voting Control [Member]", "label": "Maintains Voting Control [Member]", "terseLabel": "Maintains Voting Control" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MajorCustomersAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r285", "r1083", "r1086", "r1168", "r1173", "r1558", "r1560", "r1561", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "fbio_ManagementServicesAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ManagementServicesAgreementsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Management Services Agreements [Member]", "label": "Management Services Agreements [Member]", "terseLabel": "Management Services Agreements" } } }, "auth_ref": [] }, "fbio_MarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MarketOfferingMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "auth_ref": [] }, "fbio_MaximumAmountOfEquitySecuritiesToBeRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MaximumAmountOfEquitySecuritiesToBeRaised", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents maximum amount of equity securities to be raised by the company.", "label": "Maximum Amount Of Equity Securities to be Raised", "terseLabel": "Capitalization in equity securities" } } }, "auth_ref": [] }, "fbio_MaximumAmountsToBeReceivedOnThirdPartyLicensingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MaximumAmountsToBeReceivedOnThirdPartyLicensingRevenue", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum amounts to be received on third party licensing revenue.", "label": "Maximum Amounts To be Received On Third Party Licensing Revenue", "terseLabel": "Maximum amounts to be received on third party licensing revenue" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r242", "r390", "r391", "r392", "r393", "r498", "r528", "r529", "r530", "r547", "r689", "r787", "r885", "r887", "r894", "r931", "r932", "r990", "r995", "r999", "r1000", "r1002", "r1014", "r1015", "r1017", "r1018", "r1032", "r1033", "r1072", "r1082", "r1098", "r1103", "r1105", "r1106", "r1145", "r1146", "r1150", "r1151", "r1169", "r1449", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r1255" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1255" ] }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount for Lack of Marketability [Member]", "terseLabel": "Discount for lack of marketability", "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly." } } }, "auth_ref": [ "r1145", "r1528", "r1529", "r1530" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected life in years", "verboseLabel": "Expected term in years", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r527", "r1528", "r1529", "r1530" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility", "verboseLabel": "Expected Volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r528", "r1145", "r1528", "r1529", "r1530" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk-free rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r530", "r1528", "r1529", "r1530" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "terseLabel": "Stock price", "verboseLabel": "Exercise price", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r1528", "r1529", "r1530" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r526", "r527", "r528", "r529", "r530", "r531", "r687", "r688", "r689", "r1103", "r1105", "r1106", "r1145" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r687", "r688", "r689", "r1103", "r1105", "r1106", "r1145" ] }, "fbio_MergerAgreementContingentCashConsiderationReceivableForEachOutstandingSharesUponAchievementOfMilestoneCondition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MergerAgreementContingentCashConsiderationReceivableForEachOutstandingSharesUponAchievementOfMilestoneCondition", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contingent cash consideration Receivable for each share of outstanding stock upon achievement of milestone condition pursuant to a merger agreement.", "label": "Merger Agreement, Contingent Cash Consideration Receivable For Each Outstanding Shares, Upon Achievement Of Milestone Condition", "terseLabel": "Contingent cash consideration upon achievement of milestone" } } }, "auth_ref": [] }, "fbio_MergerAgreementMilestoneDeadlineDateDeterminationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MergerAgreementMilestoneDeadlineDateDeterminationTerm", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Period after the date on which marketing authorization application or equivalent receives positive validation used for determining milestone deadline date expressed in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Merger Agreement, Milestone Deadline Date Determination Term", "terseLabel": "Milestone deadline date determination term" } } }, "auth_ref": [] }, "fbio_Mergeragreementmaximumcontingentconsiderationpershareforeachoutstandingshares": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "Mergeragreementmaximumcontingentconsiderationpershareforeachoutstandingshares", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contingent consideration recognized for each share of outstanding stock pursuant to a merger agreement.", "label": "MergerAgreementMaximumContingentConsiderationPerShareForEachOutstandingShares", "terseLabel": "Maximum contingent consideration per each outstanding share" } } }, "auth_ref": [] }, "fbio_MilestonePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MilestonePaid", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of milestone paid", "label": "Milestone paid", "terseLabel": "Milestone paid" } } }, "auth_ref": [] }, "fbio_MilestonePaymentsReceivableLicensingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MilestonePaymentsReceivableLicensingAgreements", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments receivable upon occurrence of certain events or achievement of certain milestones.", "label": "Milestone Payments Receivable, Licensing Agreements", "terseLabel": "Sales milestone payments receivable" } } }, "auth_ref": [] }, "fbio_MilestonesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MilestonesPayable", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additional milestones payable under the agreement.", "label": "Milestones Payable", "terseLabel": "Additional milestones payable" } } }, "auth_ref": [] }, "fbio_MinimumLiquidityToBeMaintained": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MinimumLiquidityToBeMaintained", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents minimum liquidity to be maintained as per the debt agreement.", "label": "Minimum Liquidity to be Maintained", "terseLabel": "Minimum liquidity to be maintained" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r242", "r390", "r391", "r392", "r393", "r498", "r528", "r529", "r530", "r547", "r689", "r787", "r885", "r887", "r894", "r931", "r932", "r990", "r995", "r999", "r1000", "r1002", "r1014", "r1015", "r1017", "r1018", "r1032", "r1033", "r1072", "r1082", "r1098", "r1103", "r1105", "r1106", "r1145", "r1146", "r1150", "r1169", "r1449", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554" ] }, "fbio_MinimumNetSaleTrailingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MinimumNetSaleTrailingPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Trailing period duration for maintaining minimum net sales.", "label": "Minimum Net Sale Trailing Period", "terseLabel": "Minimum net sale trailing period" } } }, "auth_ref": [] }, "fbio_MinimumNetSalesToBeAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MinimumNetSalesToBeAchieved", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of net sales to be achieved.", "label": "Minimum Net Sales To Be Achieved", "terseLabel": "Net sales" } } }, "auth_ref": [] }, "fbio_MinimumNetSalesToBeMaintained": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MinimumNetSalesToBeMaintained", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents minimum net sales to be maintained, on a trailing 12-month basis, as per the debt agreement.", "label": "Minimum Net Sales to be Maintained", "terseLabel": "Minimum net sales to be maintained" } } }, "auth_ref": [] }, "fbio_MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum ownership interest in subsidiaries for consolidated income tax return.", "label": "Minimum ownership interest in subsidiaries for consolidated income tax return", "terseLabel": "Minimum ownership interest in subsidiaries for consolidated income tax return" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r72", "r115", "r188", "r191", "r192", "r326", "r398", "r401", "r402", "r403", "r407", "r408", "r849", "r943", "r1535" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterests" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest Disclosure [Text Block]", "verboseLabel": "Non-Controlling Interests", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r108" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsScheduleOfNonControllingInterestsInConsolidatedEntitiesDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsScheduleOfNonControllingInterestsInConsolidatedEntitiesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "verboseLabel": "Non-controlling ownership", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsScheduleOfNonControllingInterestsInConsolidatedEntitiesDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": [ "r48", "r49", "r72", "r78" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1275" ] }, "fbio_MonthlyCashDividendPerSharePayable": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MonthlyCashDividendPerSharePayable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Monthly cash dividend per share payable", "label": "Monthly Cash Dividend Per Share Payable", "terseLabel": "Monthly cash dividend" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1283" ] }, "fbio_MustangTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "MustangTherapeuticsIncMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Mustang Therapeutics Inc.", "label": "Mustang", "terseLabel": "Mustang" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r285", "r1083", "r1086", "r1168", "r1173", "r1558", "r1560", "r1561", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1256" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r181" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r181" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r91", "r92", "r93" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Fortress", "verboseLabel": "Net income (loss) attributable to common stockholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r81", "r93", "r118", "r140", "r145", "r163", "r164", "r168", "r188", "r191", "r192", "r196", "r203", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r223", "r326", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r441", "r444", "r447", "r452", "r535", "r596", "r652", "r683", "r710", "r858", "r960", "r982", "r983", "r1049", "r1051", "r1053", "r1190", "r1445" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Attributable to non-controlling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r52", "r109", "r163", "r164", "r211", "r214", "r215", "r857", "r1341" ] }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "negatedLabel": "Net income (loss) attributable to non-controlling interest", "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest." } } }, "auth_ref": [ "r78" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r140", "r172", "r207", "r208", "r209", "r210", "r218", "r219", "r224", "r227", "r444", "r447", "r452", "r652" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "fbio_NewYorkNyOfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NewYorkNyOfficeSpaceMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "New York, NY Office Space [Member]", "terseLabel": "New York, NY Office Space" } } }, "auth_ref": [] }, "fbio_NonControllingInterestsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NonControllingInterestsPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "It represents of non-controlling interests Policies.", "label": "Non controlling Interests Policy Text Block", "verboseLabel": "Non-Controlling Interests" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r1255" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1263", "r1272" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1246" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1245" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r1263" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1283" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1283" ] }, "fbio_NonRule10b51ArrangementModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NonRule10b51ArrangementModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Non-Rule 10b5-1 Arrangement Modified [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Non-Controlling Interests" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Deconsolidation", "negatedLabel": "Deconsolidation of subsidiary non-controlling interests", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest." } } }, "auth_ref": [ "r10", "r41" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interests", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r47", "r461", "r1400", "r1401", "r1402", "r1403", "r1596" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r83" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_NonrecurringAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonrecurringAdjustmentAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Nonrecurring Adjustment [Axis]", "documentation": "Information by nonrecurring adjustment directly attributable to business combination included in reported pro forma revenue and earnings." } } }, "auth_ref": [ "r615", "r616", "r1103", "r1107" ] }, "us-gaap_NonrecurringAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonrecurringAdjustmentDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Nonrecurring Adjustment [Domain]", "documentation": "Nonrecurring adjustment directly attributable to business combination included in reported pro forma revenue and earnings." } } }, "auth_ref": [ "r615", "r616", "r1103", "r1107" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "verboseLabel": "Schedule of Restricted Stock Awards and Restricted Stock Units", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r13" ] }, "fbio_November2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "November2023WarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to November 2023 Warrants.", "label": "November 2023 Warrants [Member]", "terseLabel": "November 2023 Warrants" } } }, "auth_ref": [] }, "fbio_NumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfCustomers", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of customers.", "label": "Number of Customers", "verboseLabel": "Number of customers" } } }, "auth_ref": [] }, "fbio_NumberOfDaysToDisposeOfAssetsPurchased": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfDaysToDisposeOfAssetsPurchased", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days within which the entity is obligated to sell, or otherwise dispose of, the assets purchased, pursuant to National Security Agreement.", "label": "Number Of Days To Dispose Of Assets Purchased", "terseLabel": "Number of days to dispose of assets purchased" } } }, "auth_ref": [] }, "fbio_NumberOfPartnerCompaniesThatArePubliclyTraded": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfPartnerCompaniesThatArePubliclyTraded", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of partner companies that are publicly traded.", "label": "Number Of Partner Companies That Are Publicly Traded", "terseLabel": "Number of partner companies that are publicly traded" } } }, "auth_ref": [] }, "fbio_NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of partner companies that have consummated strategic partnerships with industry leaders.", "label": "Number Of Partner Companies That Have Consummated Strategic Partnerships With Industry Leaders", "terseLabel": "Number of partner companies that have consummated strategic partnerships with industry leaders" } } }, "auth_ref": [] }, "fbio_NumberOfReportableSegmentsNotDisclosedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfReportableSegmentsNotDisclosedFlag", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the number of reportable segments not disclosed flag.", "label": "Number Of Reportable Segments Not Disclosed Flag", "terseLabel": "Number of reportable segments not disclosed flag" } } }, "auth_ref": [] }, "fbio_NumberOfSalesBasedMilestones": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfSalesBasedMilestones", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of sales-based milestones", "label": "Number Of Sales-Based Milestones", "terseLabel": "Number of sales milestones" } } }, "auth_ref": [] }, "fbio_NumberOfSharesIssuableForAtMarketOffering": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfSharesIssuableForAtMarketOffering", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Shares issuable for At-the-Market offering", "label": "Number of Shares issuable for At-the-Market offering", "terseLabel": "Number of Shares issuable for At-the-Market offering" } } }, "auth_ref": [] }, "fbio_NumberOfTranchesOfSharesToBeIssued": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "NumberOfTranchesOfSharesToBeIssued", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of tranches of shares to be issued under the agreement", "label": "Number Of Tranches Of Shares To Be Issued", "terseLabel": "Number of tranches of shares" } } }, "auth_ref": [] }, "fbio_OaktreeNote2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OaktreeNote2Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Oaktree Notes.", "label": "Oaktree Note 2 [Member]", "terseLabel": "2020 Oaktree Note" } } }, "auth_ref": [] }, "fbio_OaktreeNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OaktreeNoteMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Oaktree Notes.", "label": "Oaktree Note [Member]", "terseLabel": "Oaktree Note", "verboseLabel": "2024 Oaktree Note" } } }, "auth_ref": [] }, "fbio_OaktreeWarrants2024And2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OaktreeWarrants2024And2025Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2024 and 2025 Oaktree warrants.", "label": "Oaktree Warrants 2024 And 2025 [Member]", "terseLabel": "2024 and 2025 Oaktree warrants" } } }, "auth_ref": [] }, "fbio_OaktreeWarrants2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OaktreeWarrants2025Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Okatree warrants issued in conjunction with debt in 2025.", "label": "Oaktree Warrants 2025 [Member]", "terseLabel": "2025 Oaktree Warrants" } } }, "auth_ref": [] }, "fbio_OaktreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OaktreeWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Okatree warrants issued in conjunction with debt.", "label": "Oaktree Warrants [Member]", "terseLabel": "2024 Oaktree Warrants" } } }, "auth_ref": [] }, "fbio_OncogenuityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OncogenuityMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Oncogenuity.", "label": "Oncogenuity [Member]", "terseLabel": "Oncogenuity" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r121", "r1049", "r1053", "r1060", "r1407", "r1413", "r1414", "r1415", "r1416" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r733", "r1154" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1541" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment loss allocated to right-of-use asset", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1540" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Lease Liability" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails", "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Net operating lease liabilities, short-term and long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r729" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liabilities, short-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r729" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities, long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r729" ] }, "fbio_OperatingLeaseLiabilityReversed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OperatingLeaseLiabilityReversed", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of operating lease liability reversed.", "label": "Operating Lease Liability, Reversed", "terseLabel": "Mustang lease liability" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "negatedTerseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r730", "r736" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r728" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Reduction in the carrying amount of operating lease right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1387" ] }, "fbio_OperatingLeaseRightOfUseAssetWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OperatingLeaseRightOfUseAssetWriteOff", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of write off of the operating lease right of use asset.", "label": "Operating Lease Right of Use Asset, Write Off", "terseLabel": "Right of use assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r739", "r1154" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease term - operating leases (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r738", "r1154" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "verboseLabel": "Net operating losses (NOLs)", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r582" ] }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwardsExpirationDate", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards, Expiration Date", "verboseLabel": "Net operating losses (NOLs), expiration", "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format." } } }, "auth_ref": [ "r582" ] }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwardsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Operating Loss Carryforwards", "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r1499" ] }, "fbio_OperatingLossCarryforwardsWithoutExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OperatingLossCarryforwardsWithoutExpiration", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws", "label": "Operating Loss Carryforwards Without Expiration", "terseLabel": "Operating loss carryforwards without expiration" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "Organization and Description of Business", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r94", "r108", "r1389" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r58" ] }, "us-gaap_OtherAffiliatesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAffiliatesMember", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Affiliates [Member]", "terseLabel": "Related party", "documentation": "A category that identifies other affiliates." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r153" ] }, "fbio_OtherDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OtherDebtMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Debt [Member]", "label": "Other Debt [Member]", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Income", "terseLabel": "Other revenue", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r865", "r962", "r1004", "r1005", "r1006", "r1175", "r1177" ] }, "fbio_OtherLegacyProductRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OtherLegacyProductRevenueMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Legacy Product Revenue Member.", "label": "Other Legacy Product Revenue", "terseLabel": "Other / legacy product revenue" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r58", "r1155" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r64" ] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income", "verboseLabel": "Other income (expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r85", "r1138" ] }, "fbio_OtherPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OtherPartnersMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Partners [Member]", "label": "Other Partners [Member]", "terseLabel": "Other" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1255" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1270" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r1219", "r1230", "r1240", "r1273" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1219", "r1230", "r1240", "r1273" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OwnershipAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsScheduleOfNonControllingInterestsInConsolidatedEntitiesDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OwnershipDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsScheduleOfNonControllingInterestsInConsolidatedEntitiesDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "fbio_OwnershipPercentageOfSubsidiaryToConsolidateTheirAccounts": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OwnershipPercentageOfSubsidiaryToConsolidateTheirAccounts", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Ownership percentage of the subsidiary to consolidate their accounts", "label": "Ownership percentage of the subsidiary to consolidate their accounts" } } }, "auth_ref": [] }, "fbio_OwnershipRatioOfPreferredStockAndCommonStock": { "xbrltype": "pureItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "OwnershipRatioOfPreferredStockAndCommonStock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the ownership ratio of preferred stock and common stock.", "label": "Ownership Ratio of Preferred Stock and Common Stock", "terseLabel": "Ownership Ratio of preferred Stock and common Stock" } } }, "auth_ref": [] }, "fbio_PaidInKindDividendAsPercentageOfFullyDilutedOutstandingCapitalization": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PaidInKindDividendAsPercentageOfFullyDilutedOutstandingCapitalization", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Paid in Kind dividend as a percentage of fully diluted outstanding capitalization.", "label": "Paid in Kind dividend as a percentage of fully diluted outstanding capitalization", "terseLabel": "PIK dividend as a percentage of fully diluted outstanding capitalization" } } }, "auth_ref": [] }, "fbio_ParentCompanyAndItsSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ParentCompanyAndItsSubsidiariesMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to parent company its subsidiaries.", "label": "Parent Company And Its Subsidiaries [Member]", "terseLabel": "Parent Company And Its Subsidiaries" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ParentMember", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "fbio_PartnerCompanyAccountsPayableWriteOffRelatedToRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyAccountsPayableWriteOffRelatedToRepurchaseTransaction", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of Partner company accounts payable write-off related to repurchase transaction.", "label": "Partner company accounts payable write-off related to repurchase transaction", "terseLabel": "Partner company accounts payable write-off related to repurchase transaction" } } }, "auth_ref": [] }, "fbio_PartnerCompanyAccountsReceivableWriteOffRelatedToRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyAccountsReceivableWriteOffRelatedToRepurchaseTransaction", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange of partner company accounts receivable write-off related to repurchase transaction", "label": "Partner company accounts receivable write-off related to repurchase transaction", "terseLabel": "Partner company accounts receivable write-off related to repurchase transaction" } } }, "auth_ref": [] }, "fbio_PartnerCompanyContingentCallOptionAccretionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyContingentCallOptionAccretionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Partner company contingent call option accretion.", "label": "Partner Company Contingent Call Option Accretion [Member]", "terseLabel": "Partner company contingent call option accretion" } } }, "auth_ref": [] }, "fbio_PartnerCompanyConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyConvertiblePreferredSharesMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Partner Company Convertible Preferred Shares [Member]", "label": "Partner Company Convertible Preferred Shares [Member]", "terseLabel": "Partner company convertible preferred shares" } } }, "auth_ref": [] }, "fbio_PartnerCompanyEquityOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyEquityOffering", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Partner company's equity offering, excluding at-the-market issuances.", "label": "Partner Company Equity Offering", "terseLabel": "Partner companies' offerings, net" } } }, "auth_ref": [] }, "fbio_PartnerCompanyExerciseOfOptionsForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyExerciseOfOptionsForCash", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Partner company's exercise of stock options for the purpose of cash.", "label": "Partner company exercise of options for cash", "terseLabel": "Partner company's exercise of options for cash" } } }, "auth_ref": [] }, "fbio_PartnerCompanyInstallmentPaymentsLicenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyInstallmentPaymentsLicenses", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of partner company installment payments - licenses.", "label": "Partner Company Installment Payments, Licenses", "terseLabel": "Partner company installment payments licenses" } } }, "auth_ref": [] }, "fbio_PartnerCompanyInstallmentPaymentsLicensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyInstallmentPaymentsLicensesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Partner company installment payments - licenses, short-term, net of imputed interest.", "label": "Partner company installment payments - licenses, current", "verboseLabel": "Partner company installment payments - licenses, short-term" } } }, "auth_ref": [] }, "fbio_PartnerCompanyInstallmentPaymentsNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyInstallmentPaymentsNumberOfInstallments", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of installments in which the outstanding obligation under the agreement is payable.", "label": "Partner Company Installment Payments, Number of Installments" } } }, "auth_ref": [] }, "fbio_PartnerCompanyInstallmentPaymentsSettlementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyInstallmentPaymentsSettlementAmount", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of partner company installment payment obligations agreed to be settled under the agreement during the period.", "label": "Partner Company Installment Payments, Settlement Amount" } } }, "auth_ref": [] }, "fbio_PartnerCompanyNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyNotesPayableMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to Partner Company notes payable.", "label": "Partner Company Notes Payable [Member]", "verboseLabel": "Partner company notes payable" } } }, "auth_ref": [] }, "fbio_PartnerCompanyRedeemablePerpetualPreferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanyRedeemablePerpetualPreferredLiability", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount of partner company redeemable perpetual preferred liability, as of the reporting date.", "label": "Partner Company Redeemable Perpetual Preferred Liability", "terseLabel": "Partner company redeemable perpetual preferred liability" } } }, "auth_ref": [] }, "fbio_PartnerCompanySNetPurchaseConsiderationOfAssetsRecordedToAccruedOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PartnerCompanySNetPurchaseConsiderationOfAssetsRecordedToAccruedOther", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of Partner company's net purchase consideration of assets recorded to accrued other.", "label": "Partner company's net purchase consideration of assets recorded to accrued other", "negatedLabel": "Partner company's deferred purchase consideration" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1244" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses" } } }, "auth_ref": [] }, "fbio_PaymentOfOaktreeNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PaymentOfOaktreeNote", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to the Oaktree Note.", "label": "Payment of Oaktree Note", "negatedLabel": "Repayment of Oaktree Note and debt issuance costs" } } }, "auth_ref": [] }, "fbio_PaymentOfUpfrontFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PaymentOfUpfrontFees", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment of Upfront Fees", "label": "Payment of Upfront Fees", "terseLabel": "Upfront fees paid" } } }, "auth_ref": [] }, "fbio_PaymentsAsPercentageOfFinancingProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PaymentsAsPercentageOfFinancingProceeds", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Total payments made as a percentage of financing proceeds under the terms of agreement.", "label": "Payments As A Percentage Of Financing Proceeds", "terseLabel": "Total payments made" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Rent", "verboseLabel": "Total payment for rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "terseLabel": "Contingent fees paid", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r89" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "verboseLabel": "Amount paid an origination fee", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r18" ] }, "fbio_PaymentsOfDebtYieldProtectionPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PaymentsOfDebtYieldProtectionPremium", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for yield protection premium of long-term debt.", "label": "Payments of Debt, Yield Protection Premium", "terseLabel": "Yield protection premium" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Partner company's dividends declared and paid", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r89" ] }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedLabel": "Payment of Series A perpetual preferred stock dividends", "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity." } } }, "auth_ref": [ "r89" ] }, "fbio_PaymentsOfMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PaymentsOfMilestone", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents payments of milestone.", "label": "Payments of Milestone", "verboseLabel": "Payments of milestones" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Stock offering, aggregate fees paid", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Acquired intangible assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r88" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "negatedLabel": "Partner company's net purchase consideration of assets recorded to accrued other", "verboseLabel": "Cash payments", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r123", "r1517", "r1518", "r1519" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r1254" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1254" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1246" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r1263" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r1256" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1245" ] }, "fbio_PerShareAmountReducedFromSharePriceToCalculateWarrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PerShareAmountReducedFromSharePriceToCalculateWarrantPrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share amount reduced from share price to calculate warrant price.", "label": "Per Share, Amount Reduced from Share Price to Calculate Warrant Price", "terseLabel": "Per share amount reduced from share price to calculate warrant price" } } }, "auth_ref": [] }, "fbio_PercentageOfAmountOwedConvertedIntoShares": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfAmountOwedConvertedIntoShares", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of amount owed converted into shares.", "label": "Percentage Of Amount Owed Converted Into Shares", "terseLabel": "Company agreed percentage of shares to convert" } } }, "auth_ref": [] }, "fbio_PercentageOfAmountReleasedFromEscrowFund": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfAmountReleasedFromEscrowFund", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of amount released from escrow fund.", "label": "Percentage Of Amount Released From Escrow Fund", "terseLabel": "Percentage of amount released from escrow fund" } } }, "auth_ref": [] }, "fbio_PercentageOfForgivenessOnAmountOwed": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfForgivenessOnAmountOwed", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of forgiveness on the amount owed.", "label": "Percentage Of Forgiveness On Amount Owed", "terseLabel": "Forgive remaining percentage of shares" } } }, "auth_ref": [] }, "fbio_PercentageOfMarketPriceOfCommonStockForAdditionalWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfMarketPriceOfCommonStockForAdditionalWarrants", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of market price of common stock for additional warrants.", "label": "Percentage of market price of common stock for additional warrants", "terseLabel": "Percentage of market price of common stock for additional warrants" } } }, "auth_ref": [] }, "fbio_PercentageOfOutstandingLoanPrincipalAmountPrepaymentCharge": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfOutstandingLoanPrincipalAmountPrepaymentCharge", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage Of Outstanding Loan Principal Amount Prepayment Charge.", "label": "Percentage Of Outstanding Loan Principal Amount Prepayment Charge", "terseLabel": "Percent of Outstanding Loan Principal Amount for Calculation of Repayment Change" } } }, "auth_ref": [] }, "fbio_PercentageOfRentableArea": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfRentableArea", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of area rentable", "label": "Percentage of Rentable Area" } } }, "auth_ref": [] }, "fbio_PercentageOfRoyaltyOnFutureNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfRoyaltyOnFutureNetSales", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty on future net sales granted to the company.", "label": "Percentage Of Royalty On Future Net Sales", "terseLabel": "Percentage of royalty on future net sales" } } }, "auth_ref": [] }, "fbio_PercentageOfWithholdingTax": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageOfWithholdingTax", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of withholding tax under license agreement.", "label": "Percentage Of Withholding Tax", "terseLabel": "Percentage of withholding tax" } } }, "auth_ref": [] }, "fbio_PercentageReductionInRoyaltyPaymentPercentageUponLaunchOfGenericCompetitor": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageReductionInRoyaltyPaymentPercentageUponLaunchOfGenericCompetitor", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage reduction in royalty payment percentage upon launch of generic competitor.", "label": "Percentage Reduction In Royalty Payment Percentage Upon Launch of Generic Competitor", "terseLabel": "Percentage reduction in royalty payment percentage upon launch of generic competitor" } } }, "auth_ref": [] }, "fbio_PercentageToBeReceivedOnThirdPartyLicensingRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PercentageToBeReceivedOnThirdPartyLicensingRevenue", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage to be received on third party licensing revenue.", "label": "Percentage To be Received On Third Party Licensing Revenue", "terseLabel": "Percentage to be received on third party licensing revenue" } } }, "auth_ref": [] }, "fbio_PeriodNotToCompete": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PeriodNotToCompete", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Period during which entity is not to develop, commercialize, manufacture or sell any product competing with the subject under the agreement", "label": "Period Not To Compete", "terseLabel": "Period not to compete" } } }, "auth_ref": [] }, "fbio_PeriodOfAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PeriodOfAgreement", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Period during which agreement is in force.", "label": "Period Of Agreement", "terseLabel": "Agreement term" } } }, "auth_ref": [] }, "fbio_PeriodOfRoyaltyPayable": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PeriodOfRoyaltyPayable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Period during which royalty is payable.", "label": "Period Of Royalty Payable", "terseLabel": "Royalty period" } } }, "auth_ref": [] }, "fbio_PeriodOfWrittenNoticeToTerminateAgreementWithoutCause": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PeriodOfWrittenNoticeToTerminateAgreementWithoutCause", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "The period during which written notice must be given to terminate the agreement without cause, in 'PnYnMnDTnHnMnS'", "label": "Period Of Written Notice To Terminate The Agreement Without Cause", "terseLabel": "Termination notice period" } } }, "auth_ref": [] }, "fbio_PerpetualPreferredStockOptionalExchangeTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PerpetualPreferredStockOptionalExchangeTerm", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The period following the issuance of the shares after which shareholders may exercise an option to exchange the shares for cash or an alternate class of shares.", "label": "Perpetual Preferred Stock, Optional Exchange, Term", "terseLabel": "Exchange term" } } }, "auth_ref": [] }, "fbio_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Placement Agent Warrants [Member]", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r1247" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1303" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r1246" ] }, "fbio_PostEffectiveAmendmentOfShelfRegistration2024DecemberProspectusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PostEffectiveAmendmentOfShelfRegistration2024DecemberProspectusMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the sale of stock as per the post-effective amendment of the prospectus filed in December 2023.", "label": "Post Effective Amendment Of Shelf Registration 2024, December Prospectus [Member]", "terseLabel": "Post effective amendment of Shelf Registration 2024, December Prospectus" } } }, "auth_ref": [] }, "fbio_PostEffectiveAmendmentOfShelfRegistration2024IssuedToPreferredStockHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PostEffectiveAmendmentOfShelfRegistration2024IssuedToPreferredStockHoldersMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the sale of stock to the preferred stockholders as per the post effective amendment terms.", "label": "Post Effective Amendment Of Shelf Registration 2024, Issued To Preferred Stock Holders [Member]", "terseLabel": "Post effective amendment of Shelf Registration 2024" } } }, "auth_ref": [] }, "fbio_PostEffectiveAmendmentOfShelfRegistration2024NovemberProspectusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PostEffectiveAmendmentOfShelfRegistration2024NovemberProspectusMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the sale of stock as per the post-effective amendment of the prospectus filed in November 2023.", "label": "Post Effective Amendment Of Shelf Registration 2024, November Prospectus [Member]", "terseLabel": "Post effective amendment of Shelf Registration 2024, November Prospectus" } } }, "auth_ref": [] }, "fbio_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded warrants.", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre funded warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockAmountOfPreferredDividendsInArrears", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Amount of Preferred Dividends in Arrears", "terseLabel": "Undeclared dividends", "documentation": "Aggregate amount of cumulative preferred dividends in arrears." } } }, "auth_ref": [ "r39" ] }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendRatePerDollarAmount", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount", "verboseLabel": "Preferred Stock, quarterly dividend rate per share", "documentation": "The amount per share used to calculated dividend payments on preferred stock." } } }, "auth_ref": [ "r454" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividend Rate, Percentage", "verboseLabel": "Dividend rate percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r454", "r991", "r996", "r998", "r1003" ] }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendsAndOtherAdjustments", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Preferred A dividends declared and paid and/or cumulated, and Fortress' share of subsidiary deemed dividends", "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders." } } }, "auth_ref": [ "r23", "r1306", "r1405" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Liquidating Preference", "terseLabel": "Preferred Stock, liquidation preference per share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r36", "r37", "r67", "r1391", "r1393", "r1453" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockMember", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r1182", "r1183", "r1186", "r1187", "r1188", "r1189", "r1588", "r1596" ] }, "fbio_PreferredStockMonthlyDividendsPerSharePaused": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PreferredStockMonthlyDividendsPerSharePaused", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate monthly dividends paused during the period for each share of preferred stock.", "label": "Preferred Stock, Monthly Dividends, Per Share, Paused", "terseLabel": "Monthly dividends per share paused" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r67", "r453" ] }, "us-gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockRedemptionPricePerShare", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Redemption Price Per Share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": [ "r35", "r36", "r38" ] }, "us-gaap_PreferredStockRedemptionTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockRedemptionTerms", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Redemption Terms", "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer." } } }, "auth_ref": [ "r35", "r36" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r67", "r941" ] }, "fbio_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PreferredStockSharesDesignated", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "It represents number of preferred stock shares designated.", "label": "Preferred Stock shares designated" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r67", "r453" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r67", "r941", "r959", "r1596", "r1597" ] }, "fbio_PreferredStockToCommonStockConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PreferredStockToCommonStockConversionRatio", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "documentation": "Preferred Stock to common stock conversion ratio", "label": "Preferred Stock to common stock conversion ratio" } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively, liquidation value of $25.00 per share", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r67", "r443", "r449", "r846", "r1155" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1331" ] }, "fbio_PriorOaktreeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PriorOaktreeAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to prior Oaktree agreement.", "label": "Prior Oaktree Agreement [Member]", "terseLabel": "Prior Oaktree Agreement" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrivatePlacementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "fbio_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to private placement warrants.", "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants" } } }, "auth_ref": [] }, "fbio_ProceedsFromContractTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromContractTermination", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflows associated with the termination of contractual arrangements during the period.", "label": "Proceeds From Contract Termination", "terseLabel": "Termination paid" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "terseLabel": "Net cash increase upon deconsolidation of subsidiary", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries", "terseLabel": "Proceeds from sale of subsidiary interests", "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent)." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "positiveLabel": "Proceeds from issuance of common stock for at-the-market offering, net", "terseLabel": "Net proceeds from private placement", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "fbio_ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity excluding at-the-market offerings.", "label": "Proceeds From Issuance Of Common Stock, Excluding At-The-Market Offerings", "verboseLabel": "Proceeds from issuance of common stock for public offering, net" } } }, "auth_ref": [] }, "fbio_ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity from under the Employee Stock Purchase Plan", "label": "Proceeds from issuance of common stock under ESPP", "terseLabel": "Proceeds from issuance of common stock under ESPP" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "verboseLabel": "Proceeds from debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1386" ] }, "fbio_ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyPreferredStock", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from the issuance of (payments for the redemptions of) preferred stock to partner companies during the period.", "label": "Proceeds From Issuance Of Payments For Redemptions Of Partner Company Preferred Stock", "negatedLabel": "Partner company's redemption of preferred shares" } } }, "auth_ref": [] }, "fbio_ProceedsFromIssuanceOfSubsidiariesAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromIssuanceOfSubsidiariesAtMarketOffering", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of subsidiaries at the market offering capital contribution to the entity.", "label": "Proceeds From Issuance Of Subsidiaries At Market Offering", "verboseLabel": "Proceeds from partner companies' at-the-market offering, net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Net proceeds", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r904" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r16", "r1391", "r1394" ] }, "fbio_ProceedsFromLongTermDebtExcludingLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromLongTermDebtExcludingLineOfCredit", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt excluding line of credit initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from long-term debt Excluding Line of Credit", "terseLabel": "Proceeds from long-term debt, net" } } }, "auth_ref": [] }, "fbio_ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from partner companies' sale of stock and warrants", "label": "Proceeds From Partner Companies Sale of Stock and Warrants, Net", "terseLabel": "Proceeds from partner companies' equity offerings and warrant exercises, net" } } }, "auth_ref": [] }, "fbio_ProceedsFromRelatedPartyAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromRelatedPartyAgreement", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received from desk share agreement related to design and build out of the new office.", "label": "Proceeds from Related Party Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Proceeds from partner company's long-term debt, net", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "fbio_ProceedsFromRoyaltyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromRoyaltyPayments", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow pertaining to royalty payments.", "label": "Proceeds From Royalty Payments", "terseLabel": "Cash payments from Cutia" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromSaleOfOtherPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Other Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment", "documentation": "Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [ "r87" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Consideration received", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r87" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of fixed assets", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r87" ] }, "fbio_ProceedsFromStockAndWarrantsIssuedForExchangeOfPartnerCompanyPreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromStockAndWarrantsIssuedForExchangeOfPartnerCompanyPreferredShares", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from stock and warrants issued for exchange of partner company preferred shares.", "label": "Proceeds From Stock And Warrants Issued For Exchange Of Partner Company Preferred Shares", "terseLabel": "Stock and warrants issued for exchange of partner company preferred shares" } } }, "auth_ref": [] }, "fbio_ProceedsFromSubsidiarySEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsFromSubsidiarySEmployeeStockPurchasePlan", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow from subsidiary's employee stock purchase plan (ESPP).", "label": "Proceeds From Subsidiary's Employee Stock Purchase Plan", "terseLabel": "Proceeds from partner companies' ESPP" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Exercise of warrants for cash", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r1385" ] }, "fbio_ProceedsfromexerciseOfPartnerCompaniesOptionsAndWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProceedsfromexerciseOfPartnerCompaniesOptionsAndWarrantsNet", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising the partner companies options and warrants.", "label": "Proceeds From Exercise Of Partner Companies Options And Warrants, Net", "terseLabel": "Proceeds from exercise of partner company's options, net" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProductMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r1048", "r1053", "r1083", "r1084" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r281", "r792", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r1038", "r1048", "r1051", "r1053", "r1083", "r1084", "r1167", "r1169", "r1170", "r1174", "r1180", "r1313", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1381", "r1382", "r1383", "r1384", "r1440", "r1441", "r1558", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r281", "r792", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r1038", "r1048", "r1051", "r1053", "r1083", "r1084", "r1167", "r1169", "r1170", "r1174", "r1180", "r1313", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1381", "r1382", "r1383", "r1384", "r1440", "r1441", "r1558", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfessionalFees", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Professional Fees", "terseLabel": "Advisory fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r1051", "r1066", "r1190", "r1593", "r1595" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss", "verboseLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r140", "r145", "r163", "r164", "r180", "r188", "r191", "r192", "r196", "r203", "r211", "r214", "r215", "r326", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r441", "r535", "r596", "r652", "r656", "r659", "r660", "r683", "r710", "r831", "r833", "r856", "r914", "r960", "r982", "r983", "r1136", "r1137", "r1191", "r1341", "r1445" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "auth_ref": [] }, "fbio_PropertyPlantAndEquipmentAccumulatedImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PropertyPlantAndEquipmentAccumulatedImpairment", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for property plant and equipment.", "label": "Property, Plant and Equipment, Accumulated Impairment", "negatedLabel": "Impairment - Leasehold Improvements" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8", "r741" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r97", "r129", "r130", "r131" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r99", "r150", "r854" ] }, "fbio_PropertyPlantAndEquipmentHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PropertyPlantAndEquipmentHeldForSaleMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Member represents property, plant, and equipment held for sale.", "label": "Property Plant And Equipment Held For Sale [Member]", "terseLabel": "Property, plant, and equipment held for sale" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r741" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r741", "r836", "r854", "r1155" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r8", "r129", "r130", "r852" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r99", "r741" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful Life (Years)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "fbio_PropertyPlantAndEquipmentWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PropertyPlantAndEquipmentWriteOff", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of write off of the property plant and equipment.", "label": "Property, Plant and Equipment, Write Off", "terseLabel": "Leasehold improvements" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt (recovery) expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r171", "r176", "r333" ] }, "fbio_ProvisionToReturn": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ProvisionToReturn", "calculation": { "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to provisions to return.", "label": "Provision to return", "terseLabel": "Provision to return" } } }, "auth_ref": [] }, "fbio_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "PublicOfferingMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Public Offering [Member]", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1244" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r1244" ] }, "fbio_QbexzaAssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "QbexzaAssetPurchaseAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Qbexza asset purchase agreement", "label": "Qbexza, Asset Purchase Agreement [Member]", "terseLabel": "Qbexza Asset Purchase" } } }, "auth_ref": [] }, "fbio_QbexzaLicenseAgreementForDevelopmentAndCommercializationByCounterpartyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "QbexzaLicenseAgreementForDevelopmentAndCommercializationByCounterpartyMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Qbexza, license agreement for development and commercialization by counterparty", "label": "Qbexza, License Agreement For Development And Commercialization By Counterparty [Member]", "terseLabel": "Qbexza, License Agreement" } } }, "auth_ref": [] }, "fbio_QbrexzaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "QbrexzaMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Qbrexza [Member]", "label": "Qbrexza", "terseLabel": "Qbrexza" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r242", "r390", "r391", "r392", "r393", "r486", "r498", "r528", "r529", "r530", "r534", "r547", "r689", "r761", "r770", "r787", "r885", "r887", "r894", "r931", "r932", "r990", "r995", "r999", "r1000", "r1002", "r1014", "r1015", "r1017", "r1018", "r1032", "r1033", "r1072", "r1082", "r1098", "r1103", "r1105", "r1106", "r1145", "r1146", "r1150", "r1151", "r1169", "r1184", "r1436", "r1449", "r1529", "r1550", "r1551", "r1552", "r1553", "r1554" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r242", "r390", "r391", "r392", "r393", "r486", "r498", "r528", "r529", "r530", "r534", "r547", "r689", "r761", "r770", "r787", "r885", "r887", "r894", "r931", "r932", "r990", "r995", "r999", "r1000", "r1002", "r1014", "r1015", "r1017", "r1018", "r1032", "r1033", "r1072", "r1082", "r1098", "r1103", "r1105", "r1106", "r1145", "r1146", "r1150", "r1151", "r1169", "r1184", "r1436", "r1449", "r1529", "r1550", "r1551", "r1552", "r1553", "r1554" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "verboseLabel": "Accounts Receivable, net", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r287", "r288", "r289", "r291", "r1419" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r1211", "r1222", "r1232", "r1265" ] }, "fbio_RedemptionPriceForPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "RedemptionPriceForPreferredStock", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for preferred stock of third party.", "label": "Redemption Price for Preferred Stock" } } }, "auth_ref": [] }, "fbio_ReductionInDebtCovenantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ReductionInDebtCovenantMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to scenario in which there is reduction in debt covenants.", "label": "Reduction In Debt Covenant [Member]", "terseLabel": "Reduction in debt covenants" } } }, "auth_ref": [] }, "fbio_ReductionInMilestonePaymentsReceivableIfNetSalesExceedFourBillionYenInSingleYeardevelopmentAndRegulatoryPaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ReductionInMilestonePaymentsReceivableIfNetSalesExceedFourBillionYenInSingleYeardevelopmentAndRegulatoryPaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reduction in milestone payments receivable if net sales exceed 4 billion yen in a single year, under the agreement.", "label": "Reduction In Milestone Payments Receivable If Net Sales Exceed Four Billion Yen In A Single Year Development And Regulatory Payments Receivable", "terseLabel": "Possible reduction in milestone payments receivable" } } }, "auth_ref": [] }, "fbio_RegisteredOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "RegisteredOfferingMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Registered Offering.", "label": "Registered Offering [Member]", "terseLabel": "Registered Offering" } } }, "auth_ref": [] }, "fbio_ReimbursementPayableLicensingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ReimbursementPayableLicensingAgreements", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reimbursement payable in connection with clinical trial, under license agreement.", "label": "Reimbursement payable, Licensing Agreements", "terseLabel": "Reimbursement payable in connection with clinical trial" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r188", "r195", "r196", "r286", "r493", "r496", "r746", "r747", "r843", "r851", "r934", "r935", "r936", "r937", "r938", "r958", "r989", "r1591" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r188", "r195", "r196", "r746", "r747", "r748", "r749", "r843", "r851", "r934", "r935", "r936", "r937", "r938", "r958", "r989" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r188", "r195", "r196", "r746", "r747", "r1546" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [ "r188", "r195", "r196", "r1546" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r188", "r195", "r196", "r286", "r746", "r747", "r749", "r965", "r966", "r969" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r188", "r195", "r196", "r286", "r493", "r496", "r746", "r747", "r843", "r851", "r934", "r935", "r936", "r937", "r938", "r958", "r989", "r1546", "r1591" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r743", "r744", "r745", "r747", "r750", "r910", "r911", "r912", "r967", "r968", "r969", "r987", "r988" ] }, "fbio_RepaymentsOfDebtInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "RepaymentsOfDebtInterest", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal portion of long-term debt.", "label": "Repayments of Debt, Interest", "terseLabel": "Repayment interest" } } }, "auth_ref": [] }, "fbio_RepaymentsOfDebtPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "RepaymentsOfDebtPrincipal", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal portion of long-term debt.", "label": "Repayments of Debt, Principal", "terseLabel": "Principal repayment" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2020OaktreeNoteDetails" ], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Debt", "terseLabel": "Term Loan payoff amount", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r90", "r907" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of partner company installment payments - licenses", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r90" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r188", "r197", "r198", "r413", "r455", "r749", "r771", "r840", "r1044", "r1045", "r1046", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1520", "r1521", "r1522", "r1523" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross", "terseLabel": "Expense recognized for licenses acquired", "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r550" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "License Agreements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r549", "r1492" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff", "terseLabel": "Research and development - licenses acquired", "documentation": "Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": [ "r173", "r362", "r1035", "r1491" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "netLabel": "Research and development", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1491" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "verboseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "verboseLabel": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r548" ] }, "fbio_ResearchAndDevelopmentExpenseStockBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ResearchAndDevelopmentExpenseStockBasedCompensation", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement relating to research and development division. Excludes amount capitalized.", "label": "Research And Development Expense, Stock Based Compensation", "terseLabel": "Stock-based compensation - Research & development" } } }, "auth_ref": [] }, "fbio_ResearchAndDevelopmentLicensesAcquiredExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ResearchAndDevelopmentLicensesAcquiredExpense", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Research and development-licenses acquired, expense", "label": "Research and development-licenses acquired, expense", "terseLabel": "Research and development - licenses acquired, expense" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r1212", "r1223", "r1233", "r1266" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r1213", "r1224", "r1234", "r1267" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r1220", "r1231", "r1241", "r1274" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r19", "r110", "r149", "r185", "r845" ] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r19", "r125", "r185" ] }, "fbio_RestrictedStockAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "RestrictedStockAndRestrictedStockUnitsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock or stock units including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock Awards and Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Awards and Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r1406", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r70", "r106", "r848", "r892", "r893", "r908", "r942", "r1155" ] }, "us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Retained Investment, Deconsolidated Subsidiary, Measurement Input", "terseLabel": "Retained investment, deconsolidated subsidiary, measurement input", "documentation": "Value of input used to measure direct or indirect retained investment in deconsolidated subsidiary." } } }, "auth_ref": [ "r661", "r1528", "r1529", "r1530" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenues from Contracts and Significant Customers" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Product revenue, net", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r119", "r120", "r233", "r248", "r249", "r271", "r277", "r281", "r283", "r285", "r481", "r482", "r483", "r792" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "verboseLabel": "Revenue Recognition/Collaboration Revenue", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r134", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r1036" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]", "terseLabel": "Revenue", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r1409", "r1410" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenues from Contracts and Significant Customers", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r134", "r464", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r483", "r485" ] }, "us-gaap_RevenueNotFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueNotFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Not from Contract with Customer", "terseLabel": "Revenue - related party", "documentation": "Amount of revenue that is not accounted for under Topic 606." } } }, "auth_ref": [ "r1315" ] }, "us-gaap_RevenueNotFromContractWithCustomerOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueNotFromContractWithCustomerOther", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue Not from Contract with Customer, Other", "terseLabel": "Revenue - related party", "documentation": "Amount of revenue that is not accounted for under Topic 606, classified as other." } } }, "auth_ref": [ "r133" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Net revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r119", "r120", "r169", "r188", "r191", "r192", "r233", "r248", "r249", "r271", "r277", "r281", "r283", "r285", "r326", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r710", "r831", "r833", "r1066", "r1138", "r1175", "r1177", "r1445" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenuesAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "negatedLabel": "Right-of-use assets exchanged for new operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r737", "r1154" ] }, "us-gaap_RoyaltyIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RoyaltyIncomeNonoperating", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Royalty Income, Nonoperating", "terseLabel": "Royalty Income", "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": [ "r83" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RoyaltyMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "terseLabel": "Royalty", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r1456", "r1457" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1283" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1283" ] }, "fbio_Rule10b51ArrangementModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "Rule10b51ArrangementModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Rule 10b5-1 Arrangement Modified [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "fbio_SaleOfStockAggregateOfferingPricePermittedByAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SaleOfStockAggregateOfferingPricePermittedByAgreement", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of Stock aggregate offering price permitted by agreement.", "label": "Sale of Stock aggregate offering price permitted by agreement", "terseLabel": "Stock offering, aggregate offering permitted by the agreement" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Sale of stock, net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received Per Transaction", "verboseLabel": "Stock offering, gross proceeds", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Stock offering, number of shares issued", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "fbio_SaleOfStockNumberOfSharesPerUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SaleOfStockNumberOfSharesPerUnit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares to be issued for each unit as per the stock transaction.", "label": "Sale of Stock, Number of Shares Per Unit", "terseLabel": "Number of share per unit issued" } } }, "auth_ref": [] }, "fbio_SaleOfStockNumberOfWarrantsPerUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SaleOfStockNumberOfWarrantsPerUnit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants to be issued for each unit as per the stock transaction.", "label": "Sale of Stock, Number of Warrants Per Unit", "terseLabel": "Number of warrants per unit issued" } } }, "auth_ref": [] }, "fbio_SaleOfStockPercentageOfSharesIssuedInTransaction": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SaleOfStockPercentageOfSharesIssuedInTransaction", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of commission agreed to be paid to the company, percentage calculated over gross proceeds from the sales of stock.", "label": "Sale of Stock, Percentage of Shares Issued in Transaction", "terseLabel": "Shares issued (in percent)" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Stock offering, price per share", "verboseLabel": "Stock purchase, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "fbio_SalesMilestonePayableLicensingAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SalesMilestonePayableLicensingAgreements", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of sales milestone payable under license agreement.", "label": "Sales Milestone Payable, Licensing Agreements", "terseLabel": "Sales milestone payable" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r141", "r142", "r216", "r499", "r1308" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accounts payable and accrued expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r228" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computation of Net Loss Per Common Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsRoyaltyAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r354", "r598", "r599", "r600", "r601", "r607", "r608", "r609", "r610", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r645", "r646", "r647", "r650", "r1103", "r1106", "r1511", "r1514", "r1515" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "verboseLabel": "Schedule of Cash and Cash Equivalents and restricted cash", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of income taxes paid (net of refunds received) by jurisdiction,", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "verboseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1503" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "verboseLabel": "Schedule of Debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1498" ] }, "fbio_ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of effective date and annual management services agreement fee income expense.", "label": "Schedule Of Effective Date And Annual Management Services Agreement Fee Income Expense [Table Text Block]", "verboseLabel": "Schedule of effective date and annual consulting fee payable by the subsidiary to the Company" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r558", "r1102", "r1493" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r44" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r323", "r324", "r325", "r592", "r710", "r1309", "r1310", "r1311", "r1506", "r1507", "r1508", "r1509" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r356", "r364", "r368", "r369", "r371", "r793", "r1035", "r1040", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1040", "r1429" ] }, "fbio_ScheduleOfIncomeTaxTable": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ScheduleOfIncomeTaxTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Income Tax [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r356", "r367", "r371", "r1040", "r1108", "r1109", "r1110", "r1119", "r1120", "r1134" ] }, "fbio_ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expenses for debt arrangements.", "label": "Schedule Of Interest Expenses For Debt Arrangements [Table Text Block]", "verboseLabel": "Interest Expense for all Debt Arrangements" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureInventoryTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r7", "r74", "r75", "r76" ] }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "verboseLabel": "Stock Based Compensation Plans of Partner Companies", "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8", "r741" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r188", "r195", "r196", "r746", "r747", "r749", "r965", "r966", "r969" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development, Contract to Perform for Others [Table]", "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding." } } }, "auth_ref": [ "r549", "r1492" ] }, "fbio_ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revaluation of warrant liability.", "label": "Schedule of Revaluation of Warrant Liability [Table Text Bloc]", "terseLabel": "Schedule of revaluation of warrant liability" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Schedule of Segment Information", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r501", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r534" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of Warrant activities", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r1455" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of unrecognized tax benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r570", "r1101" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "verboseLabel": "Schedule of future amortization of intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r1040", "r1431" ] }, "fbio_SecondAmendmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SecondAmendmentAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to second amendment to 2024 Oaktree Notes.", "label": "Second Amendment Agreement [Member]", "terseLabel": "Second Oaktree Amendment" } } }, "auth_ref": [] }, "fbio_SecondSpecifiedPeriodOrConditionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SecondSpecifiedPeriodOrConditionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to second specified period or condition.", "label": "Second Specified Period Or Condition [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1193" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1196" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r119", "r120", "r121", "r122", "r233", "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r261", "r262", "r263", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r285", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r371", "r385", "r386", "r644", "r647", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r1063", "r1066", "r1067", "r1074", "r1172", "r1558", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "fbio_SegmentExpenditureAdditionToIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SegmentExpenditureAdditionToIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expenditure for addition to intangible assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM.", "label": "Segment, Expenditure, Addition to Intangible Assets", "terseLabel": "Additions to intangible assets" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r239", "r283", "r284", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r831", "r832", "r833", "r834", "r928", "r929", "r930", "r992", "r997", "r1001", "r1007", "r1014", "r1016", "r1017", "r1018", "r1022", "r1023", "r1024", "r1025", "r1027", "r1028", "r1029", "r1030", "r1031", "r1039", "r1057", "r1083", "r1085", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1171", "r1184", "r1558", "r1560", "r1561", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r122", "r233", "r243", "r244", "r245", "r246", "r247", "r260", "r262", "r263", "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r285", "r1061", "r1064", "r1065", "r1066", "r1068", "r1070", "r1071" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]", "terseLabel": "Other Significant Items" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "verboseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r280", "r283", "r1062", "r1063", "r1069" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r82", "r1048", "r1049", "r1050", "r1053", "r1380" ] }, "fbio_SellingGeneralAndAdministrativeExpenseShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SellingGeneralAndAdministrativeExpenseShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement relating to selling, general and administration of the company as a whole. Excludes amount capitalized.", "label": "Selling, General And Administrative Expense, Share Based Compensation", "terseLabel": "Stock-based compensation - Selling, general and administrative" } } }, "auth_ref": [] }, "fbio_SentynlDevelopmentAndAssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SentynlDevelopmentAndAssetPurchaseAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Sentynl development and asset purchase agreement.", "label": "Sentynl Development and Asset Purchase Agreement [Member]", "terseLabel": "Development and Asset Purchase Agreement w/Sentynl" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r1325", "r1326", "r1451", "r1454" ] }, "fbio_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesBWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Series B Warrants", "label": "Series B Warrants [Member]", "terseLabel": "Series B Warrants", "verboseLabel": "USE MEMBER ON CLASS OF WARRANTS AXIS, NOT THIS ONE" } } }, "auth_ref": [] }, "fbio_SeriesC1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesC1WarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to series C-1 warrants.", "label": "Series C1 Warrants [Member]", "terseLabel": "Series C-1 warrants" } } }, "auth_ref": [] }, "fbio_SeriesC2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesC2WarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to series C-2 warrants.", "label": "Series C2 Warrants [Member]", "terseLabel": "Series C-2 warrants" } } }, "auth_ref": [] }, "fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesCumulativeRedeemablePerpetualPreferredStockMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Series A cumulative redeemable perpetual preferred stock.", "label": "9.375% Series A Cumulative Redeemable Perpetual Preferred Stock [Member]", "terseLabel": "9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value" } } }, "auth_ref": [] }, "fbio_SeriesOneWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesOneWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A one warrants.", "label": "Series A One Warrants [Member]", "terseLabel": "Series A One Warrants" } } }, "auth_ref": [] }, "fbio_SeriesThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesThreeWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A three warrants.", "label": "Series A Three Warrants [Member]", "terseLabel": "Series A Three Warrants" } } }, "auth_ref": [] }, "fbio_SeriesTwoWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesTwoWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A two warrants.", "label": "Series A Two Warrants [Member]", "terseLabel": "Series A Two Warrants" } } }, "auth_ref": [] }, "fbio_SeriesWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SeriesWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A Warrants", "label": "Series A Warrants [Member]", "terseLabel": "Series A Warrants" } } }, "auth_ref": [] }, "fbio_SettlementOfPartnerCompanyPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SettlementOfPartnerCompanyPayables", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the settlement of amounts payable to vendors for goods and services received but not paid.", "label": "Settlement of Partner Company Payables", "terseLabel": "Settlement of partner company payables" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Stock based compensation, vesting period", "verboseLabel": "Weighted average vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1099" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of shares, forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r520" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of shares, Granted", "verboseLabel": "Number of shares, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r518" ] }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value.", "label": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value", "terseLabel": "Fair value of stock granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r518" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of shares, unvested ending balance", "periodStartLabel": "Number of shares, unvested beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r515", "r516" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant price, unvested balance", "periodStartLabel": "Weighted average grant price, unvested balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r515", "r516" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of shares, vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r501", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r534" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Share based compensation, additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1489" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1100" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available", "verboseLabel": "Stock based compensation, shares available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Number of shares, Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r514" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares, Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r513" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Total weighted average intrinsic value, Options vested and expected to vest", "periodStartLabel": "Total weighted average intrinsic value, Options vested and expected to vest", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r523" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "verboseLabel": "Schedule of Stock Option Activities", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Options vested and expected to vest, Number of shares", "periodStartLabel": "Options vested and expected to vest, Number of shares", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r523" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options vested and expected to vest, Weighted average exercise price", "periodStartLabel": "Options vested and expected to vest, Weighted average exercise price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r523" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Share based compensation, number of shares granted", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r528", "r529", "r530", "r531" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r514" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r513" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r500", "r506", "r525", "r526", "r527", "r528", "r531", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544" ] }, "fbio_ShareRepurchaseConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ShareRepurchaseConsideration", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount paid for shares repurchased.", "label": "Share Repurchase, Consideration", "terseLabel": "Share repurchase, amount paid" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Options vested and expected to vest, Weighted average contractual life", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r523" ] }, "fbio_SharedServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SharedServicesAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Shared Services Agreement [Member]", "terseLabel": "Shared Services Agreement" } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "verboseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r1452", "r1461" ] }, "fbio_SharesExchangedForCash": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SharesExchangedForCash", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares that were exchanged for cash during the period.", "label": "Shares Exchanged For Cash", "terseLabel": "Shares exchanged for cash" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Closing price of shares", "verboseLabel": "Shares issued, price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesOutstanding", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "fbio_SharesWithheldRelatedToNetSettlementOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SharesWithheldRelatedToNetSettlementOfWarrants", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares withheld related to net settlement of warrants.", "label": "Shares Withheld Related To Net Settlement Of Warrants", "terseLabel": "Shares withheld related to net settlement of warrants" } } }, "auth_ref": [] }, "fbio_ShelfRegistration2024StatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ShelfRegistration2024StatementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Shelf Registration 2024 Statement.", "label": "Shelf Registration 2024 Statement [Member]", "terseLabel": "Shelf Registration 2024 Statement" } } }, "auth_ref": [] }, "fbio_ShelfRegistrationStatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ShelfRegistrationStatementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Shelf Registration Statement [Member]", "label": "Shelf Registration Statement [Member]", "terseLabel": "Shelf Registration Statement" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r186", "r187" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r556" ] }, "us-gaap_StateAndLocalTaxJurisdictionOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StateAndLocalTaxJurisdictionOtherMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Tax Jurisdiction, Other [Member]", "terseLabel": "Other", "documentation": "Designated state and local jurisdiction entitled to levy and collect income tax in country of domicile, classified as other." } } }, "auth_ref": [ "r1388", "r1500" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r119", "r120", "r121", "r122", "r143", "r233", "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r261", "r262", "r263", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r285", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r371", "r375", "r385", "r386", "r644", "r647", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r1063", "r1066", "r1067", "r1074", "r1172", "r1558", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsBoardServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r136", "r156", "r157", "r158", "r188", "r192", "r221", "r222", "r225", "r227", "r235", "r236", "r326", "r398", "r401", "r402", "r403", "r407", "r408", "r442", "r443", "r445", "r446", "r448", "r451", "r453", "r454", "r456", "r457", "r459", "r710", "r904", "r905", "r906", "r907", "r915", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r941", "r961", "r984", "r1008", "r1009", "r1010", "r1011", "r1012", "r1307", "r1393", "r1395", "r1404" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r68", "r71", "r72", "r137", "r139", "r140", "r166", "r167", "r168", "r200", "r201", "r202", "r204", "r211", "r213", "r215", "r234", "r327", "r328", "r373", "r440", "r461", "r535", "r584", "r585", "r593", "r594", "r595", "r597", "r651", "r652", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r714", "r715", "r716", "r717", "r718", "r719", "r724", "r726", "r742", "r859", "r889", "r890", "r891", "r915", "r984" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r239", "r283", "r284", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r831", "r832", "r833", "r834", "r928", "r929", "r930", "r992", "r997", "r1001", "r1007", "r1014", "r1016", "r1017", "r1018", "r1022", "r1023", "r1024", "r1025", "r1027", "r1028", "r1029", "r1030", "r1031", "r1039", "r1057", "r1083", "r1085", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1171", "r1184", "r1558", "r1560", "r1561", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "verboseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r200", "r201", "r202", "r234", "r442", "r443", "r445", "r448", "r726", "r792", "r899", "r916", "r927", "r933", "r934", "r935", "r936", "r937", "r938", "r941", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r954", "r955", "r956", "r957", "r958", "r963", "r964", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r984", "r1051", "r1053", "r1185", "r1591" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Changes in Stockholders' Equity" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquitySeriesCumulativeRedeemablePerpetualPreferredStockDividendsDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r141", "r142", "r216", "r499", "r1308", "r1312" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r200", "r201", "r202", "r234", "r286", "r442", "r443", "r445", "r448", "r726", "r792", "r899", "r916", "r927", "r933", "r934", "r935", "r936", "r937", "r938", "r941", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r954", "r955", "r956", "r957", "r958", "r963", "r964", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r984", "r1051", "r1053", "r1185", "r1591" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r1215", "r1226", "r1236", "r1269" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "fbio_StockIssuedDuringPeriodSharesCommonSharesForDirectOfferingInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "StockIssuedDuringPeriodSharesCommonSharesForDirectOfferingInShares", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period for direct offering.", "label": "Stock Issued During Period Shares Common Shares for Direct Offering (in Shares)", "terseLabel": "Issuance of common shares - Registered direct offering" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under ESPP (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r11", "r67", "r68", "r106" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "positiveLabel": "Issuance of common stock for equity offering, net (in shares)", "terseLabel": "Issuance of stock for equity offerings, net (in shares)", "verboseLabel": "Shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r67", "r68", "r106", "r904", "r984", "r1009" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to equity plans (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r11", "r67", "r68", "r106" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of shares, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r67", "r68", "r106", "r512" ] }, "fbio_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of warrants for cash (in shares)", "verboseLabel": "Number of shares issued upon exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under ESPP", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r11", "r67", "r68", "r106" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAvenueSubscriptionAndForgivenessAgreementDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of stock for equity offerings, net", "verboseLabel": "Aggregate purchase price", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r11", "r67", "r68", "r106", "r915", "r984", "r1009", "r1191" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to equity plans", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r43", "r67", "r68", "r106" ] }, "fbio_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of warrants for cash" } } }, "auth_ref": [] }, "fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsAmount", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contingent fee payable on the proceeds of future financings.", "label": "Stock Repurchase Program, Contingent Fee Payable on Proceeds of Future Financings, Amount", "terseLabel": "Contingent fee payable from proceeds of future financing" } } }, "auth_ref": [] }, "fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsPercent", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of contingent fee payable on the proceeds of future financings.", "label": "Stock Repurchase Program, Contingent Fee Payable on Proceeds of Future Financings, Percent", "terseLabel": "Percentage of contingent fee payable" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' equity attributed to the Company", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r68", "r71", "r72", "r95", "r943", "r959", "r985", "r986", "r1155", "r1192", "r1391", "r1395", "r1396", "r1426", "r1535", "r1596" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity (deficit)", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r47", "r48", "r51", "r137", "r138", "r139", "r140", "r167", "r200", "r201", "r202", "r204", "r211", "r213", "r327", "r328", "r373", "r440", "r461", "r535", "r584", "r585", "r593", "r594", "r595", "r597", "r651", "r652", "r670", "r671", "r672", "r673", "r674", "r675", "r681", "r714", "r715", "r719", "r725", "r742", "r890", "r891", "r913", "r943", "r959", "r985", "r986", "r1013", "r1175", "r1177", "r1191", "r1391", "r1395", "r1396", "r1426", "r1535", "r1596" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Sublease Income", "negatedLabel": "Shared lease costs", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r735", "r1154" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r720", "r753" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r720", "r753" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r720", "r753" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r720", "r753" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrative2024OaktreeNoteDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r720", "r753" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r752", "r754" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "fbio_SunPharmaceuticalIndustriesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SunPharmaceuticalIndustriesIncMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsCheckpointCvrAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Sun Pharmaceutical Industries, Inc.", "label": "Sun Pharmaceutical Industries, Inc [Member]", "terseLabel": "Sun Pharmaceutical Industries, Inc." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "fbio_SwkTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "SwkTermLoanMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeSwkTermLoanDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the term loan facility with SWK.", "label": "SWK Term Loan [Member]", "terseLabel": "SWK Term Loan" } } }, "auth_ref": [] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2025", "localname": "TX", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncomeTaxesPaidNetOfRefundsReceivedByJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "Texas" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r1262" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Tangible Asset Impairment Charges", "terseLabel": "Tangible asset impairment charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r54", "r100" ] }, "us-gaap_TaxCreditCarryforwardExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardExpirationDate", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Expiration Date", "verboseLabel": "Income tax credits expiration date", "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format." } } }, "auth_ref": [ "r582" ] }, "us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxJurisdictionOfDomicileExtensibleEnumeration", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Jurisdiction of Domicile [Extensible Enumeration]", "documentation": "Indicates tax jurisdiction of domicile." } } }, "auth_ref": [ "r556", "r1102" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "verboseLabel": "Income taxes payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r57", "r58" ] }, "fbio_TerminationPaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TerminationPaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of termination payments receivable under the agreement.", "label": "Termination Payments Receivable", "terseLabel": "Termination payments receivable" } } }, "auth_ref": [] }, "fbio_TgtxAndOpusPointPartnersManagementLlcOppmMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TgtxAndOpusPointPartnersManagementLlcOppmMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "TGTX and Opus Point Partners Management, LLC (\"OPPM\") [Member]", "label": "TGTX and OPPM [Member]", "terseLabel": "TGTX and OPPM" } } }, "auth_ref": [] }, "fbio_TgtxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TgtxMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "TGTX [Member]", "label": "TGTX [Member]", "terseLabel": "TGTX" } } }, "auth_ref": [] }, "fbio_ThresholdPercentageOfFullyDilutedEquityCapitalizationPosition": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ThresholdPercentageOfFullyDilutedEquityCapitalizationPosition", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold percentage of fully diluted equity capitalization position in counterparty, to be held by company, until specified amount of equity securities is raised by such counterparty.", "label": "Threshold Percentage Of Fully Diluted Equity Capitalization Position", "terseLabel": "Urica's equity position", "verboseLabel": "Shares received to maintain ownership Percentage" } } }, "auth_ref": [] }, "fbio_ThresholdPercentageOfProceedsToBeTransferred": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ThresholdPercentageOfProceedsToBeTransferred", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold percentage of proceeds from sale of assets that the company is obligated to pay to a third party.", "label": "Threshold Percentage Of Proceeds To Be Transferred", "terseLabel": "Percentage of proceeds obligated to pay" } } }, "auth_ref": [] }, "fbio_ThresholdQualifiedFinancingForExpiryOfRepurchaseOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "ThresholdQualifiedFinancingForExpiryOfRepurchaseOption", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of minimum qualified financing required for the expiry of repurchase option", "label": "Threshold Qualified Financing For The Expiry of Repurchase Option", "terseLabel": "Amount of minimum qualified financing required" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r1417", "r1545" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityLtipDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1254" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r1261" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1282" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1284" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "fbio_TransactionRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TransactionRelatedExpenses", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Expenses related to transactions having to do with sale of assets.", "label": "Transaction Related Expenses", "terseLabel": "Expenses related to transactions having to do with sale of assets." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r434", "r458", "r669", "r680", "r703", "r709", "r712", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r839", "r860", "r1141", "r1143", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1156", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1420", "r1421", "r1422", "r1423", "r1525", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1285" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1286" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1286" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1284" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1284" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1287" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r1285" ] }, "fbio_TwoThousandFifteenLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TwoThousandFifteenLongTermIncentivePlanMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Fifteen Long term Incentive Plan [Member]", "label": "2015 Long term Incentive Plan [Member]", "terseLabel": "2015 Long term Incentive Plan" } } }, "auth_ref": [] }, "fbio_TwoThousandSeventeenLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TwoThousandSeventeenLongTermIncentivePlanMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Seventeen Long term Incentive Plan [Member]", "label": "2017 Long term Incentive Plan [Member]", "terseLabel": "2017 Long term Incentive Plan" } } }, "auth_ref": [] }, "fbio_TwoThousandSixteenLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TwoThousandSixteenLongTermIncentivePlanMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Sixteen Long term Incentive Plan [Member]", "label": "2016 Long term Incentive Plan [Member]", "terseLabel": "2016 Long term Incentive Plan" } } }, "auth_ref": [] }, "fbio_TwoThousandThirteenStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TwoThousandThirteenStockIncentivePlanMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Thirteen Stock Incentive Plan [Member]", "label": "2013 Stock Incentive Plan [Member]", "terseLabel": "2013 Plan" } } }, "auth_ref": [] }, "fbio_TwoThousandTwelveEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "TwoThousandTwelveEmployeeStockPurchasePlanMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twelve Employee Stock Purchase Plan [Member]", "label": "2012 Employee Stock Purchase Plan [Member]", "terseLabel": "2012 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsAvenueDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails", "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsUricaAndPartnerCompaniesDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r655" ] }, "fbio_UbrigeneBostonBiosciencesInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UbrigeneBostonBiosciencesInc.Member", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to uBriGene (Boston) Biosciences, Inc.", "label": "UBriGene (Boston) Biosciences, Inc. [Member]", "terseLabel": "UBriGene" } } }, "auth_ref": [] }, "fbio_UnamortizedCapitalizedResearchTaxCreditsAcceleratedAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnamortizedCapitalizedResearchTaxCreditsAcceleratedAmortizationPeriod", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents accelerated amortization period of previously capitalized unamortized research tax credits.", "label": "Unamortized Capitalized Research Tax Credits, Accelerated Amortization Period", "terseLabel": "Accelerated amortization period" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1281" ] }, "fbio_UnitPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnitPricePerShare", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share price of combined unit.", "label": "Unit Price Per Share" } } }, "auth_ref": [] }, "fbio_UnpaidResearchAndDevelopmentLicenseAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnpaidResearchAndDevelopmentLicenseAcquired", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "It represents the amount of unpaid research and development licenses acquired.", "label": "Unpaid Research And Development License Acquired", "terseLabel": "Unpaid research and development licenses acquired" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "verboseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r552", "r570", "r1101" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Liability related to uncertain tax positions including accrued interest", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r568", "r1101" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "terseLabel": "Accrued interest related to uncertain tax positions", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r1496" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Reductions for lapse in statute of limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r571" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits impact effective tax rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r572", "r1101" ] }, "fbio_UnregisteredWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnregisteredWarrantsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to unregistered warrants.", "label": "Unregistered Warrants [Member]", "terseLabel": "Unregistered warrants" } } }, "auth_ref": [] }, "fbio_UnregisteredWarrantsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnregisteredWarrantsOneMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to unregistered warrants one.", "label": "Unregistered Warrants One [Member]", "terseLabel": "Unregistered Warrants One" } } }, "auth_ref": [] }, "fbio_UnregisteredWarrantsTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnregisteredWarrantsTwoMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to unregistered warrants Two.", "label": "Unregistered Warrants Two [Member]", "terseLabel": "Unregistered Warrants Two" } } }, "auth_ref": [] }, "fbio_UnvestedRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnvestedRestrictedStockMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Unvested Restricted Stock [Member]", "terseLabel": "Unvested Restricted Stock and deferred Restricted Stock" } } }, "auth_ref": [] }, "fbio_UnvestedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UnvestedRestrictedStockUnitsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested Restricted Stock units and deferred Restricted Stock units" } } }, "auth_ref": [] }, "fbio_UponOccurrenceOfDevelopmentAndRegulatoryEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UponOccurrenceOfDevelopmentAndRegulatoryEventsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to upon occurrence of development and regulatory events.", "label": "Upon Occurrence of Development And Regulatory Events [Member]", "terseLabel": "Upon occurrence of development and regulatory events" } } }, "auth_ref": [] }, "fbio_Ur1TherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "Ur1TherapeuticsIncMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAndMergerAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEquityFeesDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationPlansOfPartnerCompaniesDetails" ], "lang": { "en-us": { "role": { "documentation": "UR-1 Therapeutics, Inc [Member]", "label": "UR-1 Therapeutics, Inc [Member]", "terseLabel": "Urica" } } }, "auth_ref": [] }, "fbio_UricaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "UricaMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Urica.", "label": "Urica [Member]", "terseLabel": "Urica" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r127", "r128", "r237", "r240", "r241", "r242", "r831", "r833", "r1058" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "verboseLabel": "Increase (decrease) in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r575" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "verboseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r734", "r1154" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r1250" ] }, "fbio_VyneAssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "VyneAssetPurchaseAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Vyne asset purchase agreement", "label": "Vyne, Asset Purchase Agreement [Member]", "terseLabel": "Vyne Asset Purchase" } } }, "auth_ref": [] }, "fbio_VyneProductAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "VyneProductAcquisitionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicenseAgreementsRDAndJourneyDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the VYNE Product Acquisition", "label": "VYNE Product Acquisition [Member]", "terseLabel": "VYNE Product Acquisition" } } }, "auth_ref": [] }, "fbio_WarrantChargeInConjunctionWithOaktreeDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WarrantChargeInConjunctionWithOaktreeDebt", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount charged from warrants in conjunction with Oaktree debt.", "label": "Warrant charge in conjunction with Oaktree debt", "terseLabel": "Warrant issued in conjunction with debt" } } }, "auth_ref": [] }, "fbio_WarrantLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WarrantLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrant liabilities current.", "label": "Warrant Liabilities Current", "periodEndLabel": "Common Stock Warrant liabilities at end of period", "periodStartLabel": "Common Stock Warrant liabilities at beginning of period", "terseLabel": "Common stock warrant liabilities" } } }, "auth_ref": [] }, "fbio_WarrantLiabilityPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WarrantLiabilityPolicyPolicyTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy on freestanding warrants issued by the company.", "label": "Warrant Liability, Policy [Policy Text Block]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareScheduleOfPotentiallyDilutiveSecuritiesWouldBeExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "verboseLabel": "Warrants to purchase Common Stock", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r1182", "r1183", "r1186", "r1187", "r1188", "r1189" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeUricaOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "verboseLabel": "Warrants, fair value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1528", "r1529", "r1530" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "verboseLabel": "Warrant liability, measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r1528", "r1529", "r1530" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant expiration term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1528", "r1529", "r1530" ] }, "fbio_WarrantsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WarrantsFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants.", "label": "Warrants Fair Value Disclosure", "terseLabel": "Fair value of warrants" } } }, "auth_ref": [] }, "fbio_WarrantsIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WarrantsIssued1", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The value of warrants issued in noncash financing activities.", "label": "Warrants Issued 1", "terseLabel": "Warrants issued in conjunction with debt" } } }, "auth_ref": [] }, "fbio_WarrantsIssuedInConjunctionWithExchangeOfPartnerCompanySConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WarrantsIssuedInConjunctionWithExchangeOfPartnerCompanySConvertiblePreferredShares", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount charged from warrants in conjunction with exchange of partner company's convertible preferred shares.", "label": "Warrants issued in conjunction with exchange of partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_WarrantsIssuedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WarrantsIssuedNumber", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during the period.", "label": "Warrants Issued, Number", "terseLabel": "Warrants issued" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r220", "r227" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.fortressbiotech.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r218", "r227" ] }, "fbio_WorcesterMassachusettsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "WorcesterMassachusettsMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Worcester Massachusetts.", "label": "Worcester Massachusetts" } } }, "auth_ref": [] }, "fbio_XiminoSettlementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20251231", "localname": "XiminoSettlementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestXiminoSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "Ximino settlement member.", "label": "Ximino Settlement [Member]", "terseLabel": "Ximino settlement" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r1248" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "30", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482655/740-30-25-10" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1)(e))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481117/718-50-35-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2AG", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-50" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r1140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r1141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "942", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "942", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6" }, "r1167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r1176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-12" }, "r1177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r1178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-15" }, "r1179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r1180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r1182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1200": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1242": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1243": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1244": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1245": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1246": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1306": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r1307": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1308": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1309": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1310": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1311": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1312": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } }